Protocol: I8H-MC-BDCW  
 
 
 
 
A Phase 3, Parallel -Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and 
Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin 
Glargine in Insulin -Naïve Adults with Type 2 Diabetes  
 
 
 
[STUDY_ID_REMOVED] 
 
 
 
Approval Date:  31-May-2023 
CONFIDENTIAL  I8H-MC-BDCW  (a) 
1 Title Page   
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_566780]3209590 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Compan y requests consultation regarding release/redaction prior to any public release. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approva l of Eli Lilly and Company or its subsidiaries . 
Protocol Title:   
A Phase 3, Parallel -Design, Open -Label, Randomized Control Study to Evaluate the Efficacy 
and Safety of LY3209590 Administered Weekly Using  a Fixed Dose Escalation  Compared to 
Insulin Glargin e in Insulin -Naïve Adults with Type 2 Diabetes  
Protocol Number:  I8H-MC-BDCW  
Amendment Number:  a  
Compound : LY3209590  
Brief Title:  
Efficacy  and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation 
Compared to Insulin Glargine in Adults with Type [ADDRESS_744311] Time  
Study Phase:  3 
Acronym : QWINT -1   
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s) : 
IND: 129390  
Document ID:  VV-CLIN -109083  
Approval Date:  Protocol  Amendment (a) Electronically  Signed and  Approved  by [CONTACT_10937].   
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744312] Informati on will be provided separately .  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
3 Protocol Amendment Summary of Changes Table   
 
DOCUMENT HISTORY  
Document  Date  
Original Protocol  18-May-2022  
Amendment [a] 
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
The rationale for this amendment is to clarify dosing recommendation in response to FDA 
feedback.   
Changes and rationale are summarized in this table. Minor editorial changes are not included in 
this table.  
Section # and Name  [CONTACT_11029]  
1.1. Synopsis  Number of and d uration of 
treatment with 
antihyperglycemic medicines 
updated and tirzepatide and 
sulfonylureas added as not 
allowed diabetes treatments  Additional clarity related to 
inclusion/exclusion criteria  
1.3. Schedule of 
Activities (SoA)  Information  added about visit 
interval tolerance s for Visit [ADDRESS_744313] appropr iate 
doses based on their clinical judgment  
4.1. Overall Design  Statement detailing that PK 
sample is to be collected at Vis it 
5 for those on LY3209590 or 
insulin glargine  and timing of 
collection  cannot be the same as 
Visit 6  Clarification that Visit 5 PK sample  
should be collected for both the 
LY3209590 and insulin glargine 
treatment arms  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
4 Section # and Name  [CONTACT_11029]  
5.1. Inclusion Criteria  Number and d uration of 
treatment with 
antihyperglycemic medications 
that must be at stable 
prescreenin g doses updated  
Statement  about  use of personal  
glucometer or  continuous 
glucose monitoring   device not 
allowed added  Additional clarity related to inclusion  
criteria  
5.2. Exclusion Criteria  Dual glucose dependent 
insulinotropic peptide  
(GIP) /glucagon -like peptide -1 
(GLP -1) receptor agonist  (RA)  
(for example,  tirzep atide) added 
to excluded prior or concomitant 
medications list Added clarification that GIP/GLP -1 RA 
(for example,  tirzepatide) are excluded 
medications following marketing 
approval since initial protocol approval  
6.5. Dose Modification  Clarified instruction that median 
FBG is to be determined from 
the [ADDRESS_744314] recently recorded 
FBG readings from the 7 -day 
period prior to the site visit  
Statement s about investi gator  
having discretion to presc ribe 
basal insulin do ses other  than 
protocol recommended  that they 
should  review hypoglycemic 
epi[INVESTIGATOR_566781] , 
and treatment /clinical 
management of hypoglycemia  
were added . To address any potential confusion 
regarding timing of FBG readings used 
for dose assessment  
 
 
To emphasize that investigators may use 
their discretion to select appropriate 
doses based on their clinical judgment  
and to guide investigators for the  
treatment and clinical management of 
hypoglycemia  
[IP_ADDRESS]. LY3209590 
Dose Adjustments 
Based on Fasting Bl ood 
Glucose  
Dose adjustments for 
participants on a fixed 
dose administered by 
[CONTACT_566784] 
<80 mg/dL but no 
hypoglycemia added to dosing 
table, along with guidance for 
clinical management  
Specified the 80 -130 mg/dL as 
target  To provide clear guidance for 
LY3209590 dosing using the autoinjector 
for patients with fasting blood glucose < 
80 mg/dL but not meeting hypoglycemia -
related dose reduction criteria  
 
 
For clarificati on 
[IP_ADDRESS]. Insulin 
Glargine Dose 
Adjustments According 
to Fasting Blood 
Glucose  Specified the 80 -130 mg/dL as 
target  For clarification  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
5 Section # and Name  [CONTACT_11029]  
6.8.3. 
Antihyperglycemic 
Medications  Dual GIP/GLP -1 RAs ( for 
example,  tirzepatide) added to 
list and excluded for all study 
phases except safety follow -up Added specific Dual GIP/GLP -1 RAs 
class to table following marketing 
approval since initial protocol approval  
8.1.1. Glucose 
Monitoring  Added statement that the use of 
personal glucometer or 
continuous glucose monitoring 
is not permitted  Additional clarity related to 
inclusion/exclusion criteria  
[IP_ADDRESS]. Self -
Monitoring of Blood 
Glucose  (SMBG ) Added recommendation to 
increase frequency of blood 
glucose monitoring when fasting 
blood glucose is <80 mg/dL  To educate participants to help prevent 
hypoglycemia  
11. References  Reference added for CDC [ADDRESS_744315] guidance  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
6 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ .......... 9 
1.1. Synopsis  ................................ ................................ ................................ ............................ 9 
1.2. Schema  ................................ ................................ ................................ ............................ 14 
1.3. Schedule of  Activities (SoA)  ................................ ................................ .......................... 15 
1.3.1.  Screening Visit 1, Lead -In Visit 2, and Treatment Visits 3 -18 ................................ ......16 
1.3.2.  Treatment Visits 19 to 33, Early Discontinuation, Unscheduled 
Visits, and Safety Follow -up Visits 801 and 802  ................................ ........................... 24 
2. Introduction  ................................ ................................ ................................ ................... 31 
2.1. Study Rationale  ................................ ................................ ................................ ............... 31 
2.2. Background  ................................ ................................ ................................ ..................... 31 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 32 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 33 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 34 
2.3.3.  Overall Benefit Risk Conclusion  ................................ ................................ .................... 34 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......35 
4. Study Design  ................................ ................................ ................................ .................. 38 
4.1. Overall Design  ................................ ................................ ................................ ................ 38 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 40 
4.3. Justification for Dose  ................................ ................................ ................................ ......41 
4.4. End of Study Definition  ................................ ................................ ................................ ..41 
5. Study Population  ................................ ................................ ................................ ........... 42 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 42 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 43 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .45 
5.4. Screen Failures  ................................ ................................ ................................ ................ 46 
5.5. Criteria for Temporarily Delaying Enrollment of a Participant  ................................ .....46 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 47 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 47 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 48 
6.1.2.  Rescue Medicine for Management of Severe or Persistent 
Hyperglycemia  ................................ ................................ ................................ ................ 49 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 50 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 50 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 51 
6.5. Dose Modification  ................................ ................................ ................................ .......... 51 
6.5.1.  LY3209590 Dose Initiation and Adjustment  ................................ ................................ ..52 
6.5.2.  Insulin Glargine Dose Initiation and Adjustment  ................................ ........................... 56 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 57 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...58 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....59 
6.8.1.  Medications with Approved Weight Loss Indication  ................................ ..................... 60 
6.8.2.  Chronic Systemic Glucocorticoid Medication  ................................ ................................ 60 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
7 6.8.3.  Antihyperglycemic Medications  ................................ ................................ ..................... 61 
6.9. Nonstudy Treatment after the End of the Study  ................................ ............................. 62 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 63 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 63 
7.1.1.  Liver Chemistry Stopp ing Criteria  ................................ ................................ .................. 64 
7.1.2.  Hypersensitivity Reactions  ................................ ................................ ............................. 64 
7.1.3.  Temporary Discontinuation of Study Intervention  ................................ ......................... 64 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_744316] 
Complaints  ................................ ................................ ................................ ...................... 76 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 76 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 78 
8.3.3.  Cardiovascular Events  ................................ ................................ ................................ ....79 
8.3.4.  Systemic Hypersensitivity Reactions  ................................ ................................ .............. 79 
8.3.5.  Injection -Site Reactions  ................................ ................................ ................................ ..80 
8.3.6.  Hypoglycemia  ................................ ................................ ................................ ................. 80 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 81 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 81 
8.6. Genetics  ................................ ................................ ................................ .......................... 81 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 81 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 82 
8.9. Health Economics  ................................ ................................ ................................ ........... 82 
9. Statistical Considerations  ................................ ................................ ............................. 83 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....83 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 83 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 84 
9.3.1.  General Considerations  ................................ ................................ ................................ ...84 
9.3.2.  Primary Endpoint or Estimand Analysis ................................ ................................ ......... 84 
9.3.3.  Secondary Endpoint(s) Analysis  ................................ ................................ ..................... 86 
9.3.4.  Tertiary Endpoint(s) Analysis  ................................ ................................ ......................... 86 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 86 
9.3.6.  Other Analyses  ................................ ................................ ................................ ................ 88 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
8 9.3.7. Sensitivity Analyses  ................................ ................................ ................................ ........ 88
9.4. Interim Analysis  ................................ ................................ ................................ .............. 89
9.5. Sample Size Determination  ................................ ................................ ............................ 89
10. Supporting Documentation and Operational Considerations  ................................ ..90
10.1. Appe ndix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 90
10.1.1. Regulatory and Ethical Considerations  ................................ ................................ ........... 90
10.1.2. Financial Disclosure ................................ ................................ ................................ ........ 90
10.1.3. Informed Consent Process  ................................ ................................ .............................. 91
10.1.4. Data Protection ................................ ................................ ................................ ................ 91
10.1.5. Committees Structure ................................ ................................ ................................ ......91
10.1.6. Dissemination of Clinical Study Data ................................ ................................ ............. 92
10.1.7. Data Quality Assurance  ................................ ................................ ................................ ..93
10.1.8. Source Documents  ................................ ................................ ................................ .......... 94
10.1.9. Study and Site S tart and Closure  ................................ ................................ .................... 95
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 95
10.1.11.  Investigator Information  ................................ ................................ ................................ .95
10.1.12.  Sample Retention  ................................ ................................ ................................ ............ 96
10.2. Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 97
10.2.1. Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity  Event  ................................ ................................ ................................ ..100
10.3. Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Fol low-
up, and Reporting  ................................ ................................ ................................ .......... [ADDRESS_744317] Complaints  ................................ ................................ ................. 104
10.3.4. Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ .................... 104
10.3.5. Reporting of SAEs  ................................ ................................ ................................ ........ 106
10.3.6. Regulatory Reporting Requirements  ................................ ................................ ............. 107
10.4. Appendix 4: Contraceptive and Barrier Guidance  ................................ ........................ 108
10.4.1. Definitions ................................ ................................ ................................ ..................... 108
10.4.2. Contraception Guidance ................................ ................................ ................................ 109
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Asse ssments  ................................ ................................ ................................ .................. 111
10.6. Appendix 6: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ .......... 113
10.7.  Appendix 7: Prov isions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ........................... 114
10.8.  Appendix 8: Abbreviations and Definitions  ................................ ................................ .118
11. References  ................................ ................................ ................................ .................... 122
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
9 1. Protocol Summary   
1.1. Synopsis   
Protocol Title:   
A Phase 3, Parallel -Design, Open -Label, Randomized Control Study to Evalu ate the Efficacy 
and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to 
Insulin Glargine in Insulin -Naïve Adults with Type 2 Diabetes  
Brief Title:   
Efficacy  and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation 
Compared to Insulin Glargine in Adults with Type [ADDRESS_744318] Time  
Regulatory Agency Identifier Number(s):  
IND: 129390  
Rationale : 
This Phase 3 study will  evaluate the efficacy and s afety of LY3209590  administered weekly as a 
fixed dose escalation compared with daily administration  of insulin glargine in insulin -naïve 
adult participants with type 2 diabetes ( T2D) who are starting basal insulin therapy for the first 
time.   
The fixed d ose escalation is a simplified dose escalation scheme using [ADDRESS_744319] 4 
weeks at each step to achieve the glycemic goals of fasting blood glucose ( FBG ) between 80 and 
130 mg/dL.  
This study will inform the clinical development of LY3209590.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
10 Objectives , Endpoint s, and Estimands:  
Objectives  Endpoints  
Primary  
Demonstrate noninferiority of LY3209590 compared to 
insulin glargine for the treatment of T2D in adults  Change in HbA1c from baseline to Week 52  
Key Secondary (Gated)  
Demonstrate superiority of LY3209590 compared to 
insulin glargine  Change in HbA1c from baseline to Week [ADDRESS_744320] of LY3209590 to insulin glargine 
in parameters of glycemic control   Change from baseline to Week 26 for HbA1c  
 Change from baseline to Weeks 16, 26 , and 52 for 
fasting glucose measured by [CONTACT_51964]  
 Insulin dose at Weeks 16, [ADDRESS_744321] of LY3209590 to insulin glargine 
on safety endpoints   Incidence and rate of composite of Level 2 and 3 
hypoglycemia events during the treatment period  
 Incidence and rate of composite of Level 2 and 3 
nocturnal hypoglycemia events during the 
treatment period  
 Change from baseline to Weeks [ADDRESS_744322] of LY3209590 to insulin glargine 
on patient -reported outcomes questionnaires   Change from baseline to Weeks 26 and 52 for  
o TRIM -D, and  
o DTSQ  
 Treatment experience at Weeks 26 and 52 for  
o DID-EQ, and  
o SIM-Q.  
Abbreviations: HbA1c = hemoglobin A1c; DID-EQ = Diabetes Injection Device Experience Questionnaire; SMBG 
= self -monitoring of blood glucose; SIM -Q = Simplicity Questionnaire; T2D = type 2 diabetes; TRIM -D = 
Treatment -Related Impact Measure – Diabetes.  
Primary estimand  
[LOCATION_002] registration  
The primary clinical question of interest is  
What is the treatment difference between LY3209590 and insulin glargine in HbA1c 
change from baseline to Week 52, in study eligible particip ants, regardless of treatment 
discontinuation for any reason and regardless of initiation of rescue medication?  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744323] is  
What is the treatment difference between LY3 209590 and insulin glargine in HbA1c 
change from baseline to Week 52, in study eligible participants who adhere to the 
randomized treatment without intercurrent events during the study treatment period?  
Overall Design : 
This is a Phase 3, parallel -design, o pen-label, randomized control study to evaluate the efficacy 
and safety of LY3209590 administered once -weekly compared to insulin glargine administered 
daily in adult participants with T2D that are insulin  naïve.  
The study includes a 3-week screening and lead-in period,  a 52-week treatment period, and a [ADDRESS_744324] visit in the treatment period . 
Participants will be randomly assigned  to receive daily insulin glargine or weekly insulin 
LY3209590.  
Brief Summary:  
Participants random ly assign ed to receive insulin glargine  
Participants random ly assign ed to receive insulin glargine will start on 10  U/day and will have 
weekly dose adjustments based on FBG and hypoglycemia events.  
Participants random ly assign ed to receive LY3209590  
Participants random ly assign ed to receive LY3209590 will be on a fixed dose escalation for at 
least the first 16 weeks of the study. Participants will start LY3209590 on a fixed dose of 100 U 
per week and will escalate the LY3209590 doses  every 4 weeks to the set doses of 150, 250, and 
400 U per week , as required , until an FBG of 80  to 130 mg/dL is achieved in the preceding 
week. A fixed -dose autoinjector will be used to administer each dose.  
Treat -to-target d ose adjustments will be based on FBG and hypoglycemia events.  
After Week 16, if a participant who has received the fixed dose of [ADDRESS_744325] 4 
weeks has median FBG  levels >130 mg/dL, then the investigator should transition the participant 
to titratable doses using a prefilled pen. This will provide more dosing flexibility and allow dose 
titrations above [ADDRESS_744326] continue 
using the prefilled p en for the remainder of the study.  
Study Population:  
In general, an individual may take part in the study if they  
 are ≥18 years of age at screening, or older per local regulations.  
 have a diagnosis of T2D according to the World Health Organization criteria . 
 have an HbA1c of 7.0% -10.0%, inclusive, at screening.  
 are on a stable treatment with 1 to 3 antihyperglycemic medication(s) for at least [ADDRESS_744327] label.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
12 Up to 3 of these antihyperglycemic medications are acceptable  
o DPP-4 inhibitors  
o SGLT2 inhibitors  
o biguanides, such as metformin  
o alpha -glucosidase inhibitors  
o GLP -1 receptor agonists, oral or injectable, or  
o thiazolidinediones.  
 are insulin naïve , and  
 are reliable and willing to make themselves available for the duration of the study and are 
willing and able to follow study procedures as required . 
In general, an individual may not take part in the study if they  
 have a diagnosis of type 1 diabetes , latent autoimmune diabetes, or specific type of 
diabetes other than T2D, for example, monogenic diabetes, diseases of the exocrine 
pancreas, or drug -induced or chemical -induced diabetes.  
 have received these diabetes treatments within 30 days prior to screening  
o glinides  
o pramlintide  
o sulfony lureas  
o GIP/GLP -1 RA ( for example,  tirzepatide) , or 
o insulin or any insulin containing product.  
 are women who are pregnant, lactating, or breastfeeding, or  
 have a history or presence of an underlying disease, or surgical, physical, or medical 
condition that, in the opi[INVESTIGATOR_871], would potentially affect participant 
safety within the study or interfere with the interpretation of data.  
Number of Participants:  
Approximately 670 participants will be randomly assigned to LY3209590 and insulin glargine in 
a 1:1 ratio.  
With the assumption of 15% dropout at Week 52, approximately 284 participants on LY3209590 
and 284 participants on insulin glargine will complete 52 weeks of treatment.  
Intervention Groups  and Duration : 
Participants will be random ly assign ed to receive da ily insulin glargine or weekly insulin 
LY3209590.  
The study includes a 52-week treatment period .  
Ethical Considerations of Benefit/Risk:  
Safety data available to date suggest that there is no increased risk to participants’ safety with 
LY3209590 treatmen t compared to insulin glargine . 
Participants may benefit from better  glucose  control by [CONTACT_26777] a basal insulin.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
13 Considering the information  available from previous completed clinical studies  in people , and 
the measures taken to make sure  the participants in this study  are safe , the potential risks from 
taking  LY3209590 are justified  by [CONTACT_566785] -naïve participants with T2D . 
Data Monitoring Committee: Yes 
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
14 1.2. Schema   
 
Abbreviations : FBG = fasting blood glucose ; U = units . 
 
 
[ADDRESS_744328] doseVisit 1 Visit 33
Week 52
Primary endpointVisit 2 Visit 
802Visit 18
Week 16Visit 
801Visit 8
Week 4Visit 12
Week 8Visit 16
Week [ZIP_CODE] U 
Starting dose150 U 250 U 400 U LY3209590 dose escalation
Dose assessments every 4 weeks
*Dose increased if FBG >130 mg/dL
autoinjector
Insulin glargine dose assessments every week throughout treatment period***Prefilled pen for tailored dosing if FBG
is uncontrolled at 400 U dose by [CONTACT_566786] 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
15 1.3. Schedule of Activities  (SoA)   
Two tables describe the schedule of activities.  
Table 1 (Section  1.3.1 ) summarizes procedures for Screening Visit 1, Lead -In Visit 2, and Treatment Visits 3 to 18.  
Table 2 (Section  1.3.2 ) summarizes Treatment Visits 19 to 3 3, Early Discontinuation, Unscheduled Visits, and the Safety Follow -Up 
Visits 801 and 802.  
Screening  
Screening procedures may be conducted over 1 to 3 days.  
Telehealth visits  
Telehealth visits may be by [CONTACT_517488] , or on -site if requested by [CONTACT_2299] . Gray  shaded columns in the SoA tables 
represent telehealth visits.  
Unscheduled visits  
Unscheduled visits may occur as needed. The SoA reflects some of the procedure s that may occur during these visits. Perform 
additional procedures per investigator’s discretion.  
Fasting visits  
Participants should not eat or drink anything but water for a minimum of 8 hours before a fasting visit.  
If a participant attends these visits  in a non -fasting state, the samples should be collected as non -fasting and this will not be considered 
a protocol deviation.  
Visit Interval s for Vis it 2 and Vis it 3 
The Visit 2 window will be calculated  in reference to Visit 1 : 7 days ± 3 days . 
The Visit 3 window will be calculated in reference to Visit 2 : 14 days  ± 3 days . 
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
16 1.3.1.  Screening Visit 1, Lead -In Visit 2, and Treatment Visits 3 -18  
Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744329] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
Informed consent  X                                The ICF must be signed before any 
protocol -specific tests or procedures are 
performed. See Section 10.1.[ADDRESS_744330] dose of study intervention.  
Demographics  X                                Includes ethnicity (where permissible), 
year of birth, sex, and race.  
Preexisting conditions and 
medical history, including 
relevant surgical history  X                               Collect all ongoing conditions and 
relevant past surgical and medical history.  
Prespecified medical 
history (indication and 
history of interest)  X                                 
Prior treatments for 
indication  X                                 
Substance use  
such as recreational drugs, 
alcohol, caffeine, and 
tobacco use  X                                 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
17 Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744331] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
Concomitant medications  X X X X X X X X X X X X X X X X X X  
Adverse events (AEs)  X X X X X X X X X X X X X X X X X X AEs are any events that occur after 
signing the informed consent.  
Hypoglycemia events  X X X X X X X X X X X X X X X X X X Clinical assessment based on participant 
history and e -diary entries.  
Physical Evaluation   
Height  X                                Participant should remove shoes.  
Weight  X X X   X   X       X     X   X  
Vital signs  X X X   X   X       X     X  X Include s blood pressure and pulse rate. 
Measure [ADDRESS_744332] 5 min and before 
ECG tracing and collection of blood 
samples for laboratory testing. Additional 
vital signs may be measur ed as necessary 
at investigator’s discretion.  
Physical examination  X                  Excludes pelvic, rectal, and breast 
exam ination s unless clinically indicated. 
Additional physical examinations may be 
completed as necessary at investigator’s 
discretion.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
18 Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744333] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
12-lead ECG (local)  X                  Perform ECG before any blood sample 
collection. Participants should be supi[INVESTIGATOR_51941] 5 to 10 min before 
ECG collections and remain supi[INVESTIGATOR_51942].  
ECGs may be repeat ed at the 
investigator’s discretion at any visit.  
Participant Education   
Diabetes counseling, 
training, and education   X X                Includes SMBG and hypoglycemia (see 
Sections 8.1.1  and 8.3.6 ).  
After Visit 3, conduct as needed.  
SMBG -[ADDRESS_744334] as needed.  
Electronic Participant Diary and Blood Glucose Meter   
Dispense e -diary and 
glucometer   X                 Dispense supplies as needed.  
Diary compliance check    X  X X X X X X X X X X X X X X Review entries of blood glucose , 
hypoglycemia events, and insulin dose. If 
participant is not compliant, study 
personnel will re -educate the participant 
on study requirements for continued 
study participation.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
19 Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744335] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
Review SMBG 6 -point 
profiles    X               X Review profiles collected in preceding 
week. See Section [IP_ADDRESS] . 
Paper Patient -Reported Outcomes   
Treatment -Related Impact 
Measure - Diabetes  
(TRIM -D)   X               Xc c At Visit [ADDRESS_744336] this procedure on 
the day  the change occurs.  
Diabetes Injection Device 
Experience Questionnaire 
(DID -EQ)                  X c c At Visit [ADDRESS_744337] this procedure on 
the day  the change occurs.  
Electronic Patient -Reported Outcomes   
Diabetes Treatment 
Satisfaction Questionnaire 
– Status (DTSQ -s)    X                 
Diabetes Treatment 
Satisfaction Questionnaire 
– Change (DTSQ -c)                  X c c At Visit [ADDRESS_744338] this procedure on 
the day  the change occurs.  
Simplicity of Diabetes  
Treatment Questionnaire 
(SIM -Q)                  X c c At Visit [ADDRESS_744339] this procedure on 
the day  the change occurs.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
20 Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744340] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
Basal Insulin Experience  
Likelihood of incorporating 
into routine                   X c c At Visit [ADDRESS_744341] this procedure on 
the day  the change occurs.  
Laboratory Tests and Sample Collections   
Hematology  X  X             X    
Hemoglobin A1c (HbA1c)  X  X   X  X    X    X  X  
Clinical chemistry  X  X             X    
Glucose         X    X      X  
Lipid panel    X             X    
Urinalysis  X                   
Serum pregnancy  X  X                Collect for WOCBP only.  
Urine pregnancy (local)    X                The result must be available within [ADDRESS_744342] dose of intervention.  
Perform additional pregnancy tests if a 
menstrual period is missed, if there is 
clinical suspi[INVESTIGATOR_51940], or as 
required  by [CONTACT_51967].  
Follicle -stimulating 
hormone (FSH)  X                  Perform as needed to confirm 
postmenopausal status. Definition is 
given  in Section 10.4. 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
21 Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744343] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
C-Peptide    X                 
eGFR (CKD -EPI)  X  X             X    
UACR  X  X             X    
Pharmacokinetic (PK) 
samples    X  X X  X        X  X Visit 3: collect sample at least 15 min 
after  dosing.  
Visit 5: collect sample 3 (±1) days after 
Visit 4 dose.  
For all other visits : collect at any time 
during the visit.  
Immunogenicity (ADA) 
samples    X   X  X        X  X Visit 3: collect sample before  dosing.  
If an immediate or nonimmediate 
systemic drug hypersensitivity reaction 
occurs, collect additional unscheduled 
samples as detailed in Section 10.2.[ADDRESS_744344] before dosing.  
Dosing -Related Activities   
Process visit in IWRS  X X X X X X X X X X X X X X X X X X  
Randomization using 
IWRS      X                             
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
22 Study I8H -MC-BDCW  
Table 1 Screen  
& Lead -
in Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 1a 2b 3 4 5 6 7 8 9 10 11 12 14 16 aVisit 5 occurs 3 days after Visit 4  ± 1 
day. 
Visit Interval Tolerance 
(days)   ±3 — ±3  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_744345] not occur on th e same day 
as Visit 5 . 
Visit Detail    F T   T F T T T F T T T F T F T = telehealth visit  
F = fasting visit  
Dispense LY3209590 or 
insulin glargine    X     X    X    X  X  
Dispense ancillary supplies    X                Dispense as needed . 
Dosing and injection 
training    X                Conduct as needed and if the participant 
changes from the autoinjector to the 
prefilled pen at Week 16 (Visit 1 8). 
LY3209590 or insulin 
glargine administered at 
site   X                If the participant changes from the 
autoinjector to the prefilled pen, 
administer the first dose at the site.  
Confirm participant 
administer s intervention  on 
day of visit      X                
Planned LY3209590 dose 
assessment or adjustment 
or documentation         X    X    X  X See Section 6.5 for details.  
Dose adjustments for hypoglycemia may 
occur at any time.  
Insulin glargine dose 
assessment or adjustment 
or documentation     X  X X X X X X X X X X X X X  
Assess dosing compliance     X X X X X X X X X X X X X X X  
Participant returns unused 
LY3209590 or insulin 
glargine         X    X    X  X  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
23 Abbreviations: ADA = antidrug antibody; eGFR (CKD -EPI) = estimated glomerular filtration rate (chronic kidney disease epi[INVESTIGATOR_8261]); ECG = 
electrocardiogram; ICF = informed consent form; IWRS = interactive web -response system; SMBG = self -monito ring of blood glucose; UACR = urinary 
albumin/creatinine ratio; WOCBP = women of childbearing potential.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
24 1.3.2.  Treatment Visits 1 9 to 33, Early Discontinuation, Unscheduled Visits, and Safety Follow -up Visits 801 and 802   
Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Concomitant medications  X X X X X X X X X X X X X X X X X X X  
Adverse events (AEs)  X X X X X X X X X X X X X X X X X X X See Section 10.3, Appendix 
3. 
Hypoglycemia events  X X X X X X X X X X X X X X X X X X X Clinical assessment based on 
participant history and e -
diary entries.  
Physical Evaluation   
Weight     X  X X   X   X  X X   X  
Vital signs     X  X X   X   X  X X   X Include blood pressure and 
pulse rate. Measure [ADDRESS_744346] 
5 min and before ECG 
tracing and collection of 
blood samples for laboratory 
testing. Additional vital signs 
may be measured as 
necessary at investigator’s 
discretion.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
25 Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Physical examination                X X   X Excludes pelvic, rectal, and 
breast exam ination s unless 
clinically indicated. 
Additional physical 
examinations may be 
completed as necessary at 
investigator’s discretion.  
12-lead ECG (local)                X X    Participants should be supi[INVESTIGATOR_51941] 5 to 10 
min before ECG collections 
and remain supi[INVESTIGATOR_51939].  
ECGs may be repeated at the 
investigator’s discretion at 
any visit.  
Participant Education   
Diabetes counseling, training, 
and education                     Conduct as needed.  
SMBG [ADDRESS_744347] as needed.  
Electronic Participant Diary and Blood Glucose Meter   
Dispense e -diary, glucometer                     Dispense supplies as needed.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
26 Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Diary compliance check  X X X X X X X X X X X X X X X X X X X Review entries of blood 
glucose , hypoglycemia 
events, and insulin dose. If 
participant is not compliant, 
study personnel will re -
educate the participant on 
study requirements for 
continued study 
participation.  
Review SMBG 6 -point profile        X   X     X     Review profiles collected in 
preceding week. See Section 
[IP_ADDRESS] . 
Required diary return                 X   X The diary must be returned 
on the last participant visit.  
Paper Patient -Reported Outcomes   
Treatment -Related Impact 
Measure - Diabetes  
(TRIM -D)a       X        X X    a If a participant changes 
from the autoinjector to the 
prefilled pen, conduct this 
procedure on the day  the 
change occurs.  
Diabetes Injection Device 
Experience Questionnaire  
(DID -EQ)a       X        X X    a If a participant changes 
from the autoinjector to the 
prefilled pen, conduct this 
procedure on the day  the 
change occurs.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
27 Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Electronic Patient -Reported Outcomes   
Diabetes Treatment 
Satisfaction Questionnaire – 
Change (DTSQ -c)a       X        X X     a If a participant changes 
from the autoinjector to the 
prefilled pen, conduct this 
procedure on the day the 
change occurs.  Simplicity Questionnaire 
(SIM -Q)a        X        X X    
Basal Insulin Experience  
Likelihood of incorporating 
into routinea               X X    
Laboratory Tests and Sample Collections   
Hematology        X        X X   X  
Hemoglobin A1c (HbA1c)a       X   X     X X   X a If a participant changes 
from the autoinjector to the 
prefilled pen, collect a 
sample on the day  the change 
occurs.  
Clinical chemistry        X        X X   X  
Glucoseb          X          b If a participant changes 
from the autoinjector to the 
prefilled pen, collect a 
sample on the day the change 
occurs  and before dosing. 
Collect a fasted sample,  if 
possible.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
28 Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Lipid panel        X        X X   X  
Urinalysis        X        X X   X  
Urine pregnancy (local)                 
X   X Perform additional 
pregnancy tests if a 
menstrual period is missed, if 
there is clinical suspi[INVESTIGATOR_81178], or as required by 
[CONTACT_51967].  
C-Peptide        X        X X     
eGFR (CKD -EPI)        X        X X   X  
UACR        X        X X   X  
Pharmacokinetic (PK) 
samplesc       X        X X   X c Collect sample at any time 
during the visit.  
If a participant changes from 
the autoinjector to the 
prefilled pen, collect a  
sample on the day the change  
occurs . 
Immunogenicity (ADA) 
samples        X        X X   X If an immediate or 
nonimmediate systemic drug 
hypersensitivity reaction 
occurs, collect additional 
unscheduled samples as 
detailed in Section 10.2.1 .  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
29 Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Stored Samples   
Exploratory biomarker 
samples                X X     
Dosing -Related Activities   
Process  visit in IWRS  X X X X X X X X X X X X X X X   X X Visit UV:  process  if study 
intervention dispensing is 
needed.  
Dispense LY3209590 or 
insulin glargine     X  X    X   X       Dispense as needed.  
Dispense ancillary supplies                     Dispense as needed.  
Dosing and injection training                     Conduct as needed.  
If a participant changes from 
the autoinjector to the 
prefilled pen, conduct this 
procedure when the change 
occurs.  
Observe participant 
administer LY3209590                     If the participant changes 
from the autoinjector to the 
prefilled pen, administer the 
first dose at the site.  
Planned LY3209590 dose 
assessment or adjustment and 
documentation  X X X X X X X X X X X X X X   X   See Section 6.5 for details.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
30 Study I8H -MC-BDCW  
Table 2  Treatment    Safety  
Follow -up  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ED UV 801 802  
Weeks from Randomization  17 18 19 20 22 24 26 28 32 36 40 44 48 50 52 -- -- 54 57  
Visit Interval Tolerance 
(days)  ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
3 ±
7 ±
7 ±
7 ±
7 ±
3 ±
3 ±
3 ±
3 -- -- ±7 ±7  
Visit Detail  T T T  T  F T T F T T  T F F  T  T=telehealth visit  
F=fasting visit  
Insulin glargine dose 
assessment or adjustment or 
documentation  X X X X X X X X X X X X X X   X    
Assess dosing compliance  X X X X X X X X X X X X X X X X X    
Participant returns unused 
LY3209590 or insulin 
glargine     X  X    X   X  X X     
Poststudy treatment 
assessment                X X  X X  
Abbreviations: ADA = antidrug antibody; ED = early discontinuation; eGFR (CKD -EPI) = estimated glomerular filtration rate (chronic kidney disease 
epi[INVESTIGATOR_8261]); ECG = electrocardiogram; IWRS = interactive web -response system; SMBG = self -monitoring of blood glucose; UACR = 
urinary albumin/creatinine ratio ; UV = unscheduled visit . 
 
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744348] 4 weeks at each 
step to achieve the glycemic goals of FBG between 80 and 130 mg/dL . 
This study will inform the clinical development of LY3209590.  
2.2. Background   
Current state of diabetes care  
Most people with diabetes are not achieving glycemic targets. For example , only about one 
quarter of patients with T2D on insulin and only about 30% of patients with T1D achieve the 
target glycated HbA1c of 7% and  7.5%, respectively (Blonde et al. 201 9; [LOCATION_006] National Diabetes 
Audit 2017) . 
Treatment complexity, fear of hypoglycemia, delays in insulin initiation and intensification, and 
suboptimal dosing may pose challenges to diabetes ca re. There is a need to overcome barriers to 
dose optimization with basal insulins that provide simple dosing algorithms, rapid achievement 
of glycemic targets, and a predictable profile with low likelihood of contributing to 
hypoglycemia.  
Potential for improved treatment regimens and compliance  
Once -weekly insulin using  a fixed  dose escalation could reduce treatment complexity, result in 
earlier adoption of insulin therapy that may improve treatment compliance , and lead to better 
real-world patient outco mes. Weekly insulins with a lower peak -to-trough profile during the 
week and a nearly flat insulin profile could also reduce within -day glucose variability and result 
in more consistent and predictable glycemic control  (Heis e 2021) . 
LY3209590  
LY3209590 is a novel insulin receptor agonist that is in development as a once -weekly basal 
insulin for the treatment of hyperglycemia in patients with T2D and T1D. LY3209590 has the 
potential to decrease patient burden, over come barriers to initiation of insulin therapy, and  may 
improve glycemic control and quality of life for these patients.  
A detailed description of the chemistry, pharmacology, nonclinical and clinical efficacy, and 
safety of LY3209590 is provided in the IB . 
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744349] been 
completed to assess the PK/PD, safety, and efficacy of LY3209590. The results thus far support 
continued development of LY3209590 as a treatment for diabetes mellit us.  
Pharmacokinetic and pharmacodynamic results   
Single -ascending doses of LY3209590  lowered fasting glucose in a dose - and concentration -
dependent manner, with a prolonged time -action profile.  
After multiple ascending doses over 6 weeks, maximum concentration and weekly area under the 
concentration curve ( AUC ) increased proportionally with dose.  
LY3209590 pharmacokinetics show a low peak -to-trough ratio and  extended half -life that 
supports once -weekly dosing.  
Phase [ADDRESS_744350] like LY3209590. All studies were open -
label  and degludec was the active comparator .  
The choice of study population in this study  is supported by [CONTACT_566787], conducted  in insulin -naïve participants with T2D .  
Phase 2 Study BDCL results  
Study BDCL was a randomized, open -label, comparator -controlled , treat-to-target study 
evaluating the efficacy and safety of LY3209590 compared with insulin degludec. Study 
participants  had T2D, were insulin naïve, and treated with a stable dose of metformin, alone or in 
combination with a stable dose of a DPP -4 inhibitor and/or an SGLT2 inhibitor, for at least 3 
months prior to screening.  
Participants random ly assign ed to LY3209590 achieved very good glycemic contro l during 26 
weeks of treatment . LY3209590  demonstrated  noninferiority  versus degludec for HbA1c change 
from baseline with both treatment groups achieving a mean HbA1c <7% at study endpoint and 
participa nts spending on average more than 75% of their glucose  Time in Range 70-180.  
In this open -label study, there was a low occurrence of hypoglycemia and reported TEAEs were 
similar during treatment with LY3209590 compared with degludec. In general, t he observed 
safety data were  consistent with expectations for insulin in this population. LY3209590 was well 
tolerated, and no safety findings emerged from the study that would pre vent further clinical 
development .  
 
2.3. Benefit/Risk Assessment   
Detailed information about the known and expected benefits and risks and reasonably expected  
AEs of LY3209590  may be found in the IB and that of insulin glargine ma y be found in the local 
product package insert.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
33 2.3.1.  Risk Assessment   
Potential risks for this study  
The potential risks associated with LY3209590 include  
 hypoglycemia  
 hyperglycemia  
 hypersensitivity reaction  
 injection -site reactions, for example, injection -site rash, erythema, pruritus , or 
lipohypertrophy  
 immunogenicity, and  
 cardiovascular risks.  
It is expected that the known risks would be similar to other insulins.  
Safety data available to date suggest that there is no increased risk to participants’ safety with 
LY3209590 treatment compared to insulin glargine . 
Use of a standard fixed  dose escalation  for insulin dose adjustment  is novel and, to date, 
untested.  
Management of risks 
Sections 5.1, 5.2, 6.1.[ADDRESS_744351] the insulin dose based on 
participant FBG and hypoglycemia events (see Section  6.5). The justification for the treat-to-
target dosing regimen is detailed in Section 4.3. As modifications of the basal insulin dose may 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
34 be influenced by [CONTACT_566788] c onsiderations known to the investigator, 
the investigator may prescribe a dose other than the re gimen  recommended dose. If the 
investigator prescribes a dose other than the regimen  recommended dose, the investigator is 
responsible for documenting the clini cal rationale for the prescribed dose.  
Participants will be monitored for persistent, severe hyperglycemia and will receive rescue 
therapy if this should occur (see Section 6.1.2 ).  
2.3.2.  Benefit Assessment   
Participants may benefit by [CONTACT_517491], routine safety assessments, 
and frequent engagement with health care providers during the study, which provide 
opportunities for coaching and support.  
Participants may benefit from the improvement of glycemic control promoted by [CONTACT_566789]. 
The weekly administration of LY3209590  has the potential to offer a m ore consistent glycemic 
control , while the fixed dose escalation regimen  may represent a  simple way to initiate  insulin 
treatment  for the first time . 
2.3.3.  Overall Benefit Risk Conclusion   
Considering the clinical data to date and measures taken to minimize risk for the participants in this 
study, the potential risks identified in association with LY3209590 are justified by [CONTACT_566790] -naïve p articipants with T2D.  
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
35 3. Objectives , Endpoints , and Estimands   
Objectives  Endpoints  
Primary  
Demonstrate noninferiority of LY3209590 compared to 
insulin glargine  for the treatment of T2D in adults  Change in HbA1c from baseline to Week 52  
Key Secondary ( Gated)  
Demonstrate superiority of LY3209590 compared to 
insulin glargine  Change in HbA1c from baseline to Week [ADDRESS_744352] of LY3209590 to insulin glargine  
in parameters of glycemic control   Change from baseline to Week 26 for HbA1c  
 Change from baseline to Weeks 16, 26, and 52 for 
fasting glucose measured by [CONTACT_51964]  
 Insulin dose at Weeks 16, 26, and [ADDRESS_744353] of LY3209590 to insulin glargine  
on safety endpoints   Incidence and rate of composite of Level 2 and 3 
hypoglycemia events during the treatment period  
 Incidence and rate of composite of Level 2 and 3 
nocturnal hypoglycemia events during t he 
treatment period  
 Change from baseline to Weeks [ADDRESS_744354] of LY3209590 to insulin glargine 
on patient -reported outcomes questionnaires   Change from baseline to Weeks 26 and 52 for  
o TRIM -D, and  
o DTSQ  
 Treatment experience at Weeks 26 and 52 for  
o DID-EQ, and  
o SIM-Q.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744355] of LY3209590 to insulin glargine  
for efficacy parameters   Percentage of participants at Week 52 achieving  
o HbA1c <7%  
o HbA1c <7% without nocturnal 
hypoglycemia, and  
o HbA1c ≤6.5% without hypoglycemia  
 Change from baseline to Weeks 26 and 52 for 
fasting serum glucose  
Evaluate the percentage of participants receiving 
LY3209590 that requir e a transition to the LY3209590 
prefilled pen   Percentage  of participants that require transition to 
the LY3209590 prefilled pen at Week s 26 and 52  
Evaluate  the percentage of participants at each fixed  
LY3209590  dose level   Percentage  of participants at each fixed dose level  
at Week s [ADDRESS_744356] of LY3209590 to insulin glargine  
for safety parameters   Incidence and rate of Level 2 hypoglycemia events 
during treatment period  
 Incidence and rate of Level 3 hypoglycemia events 
during treatment period  
 Incidence of positive LY3209590 tr eatment -
emergent antidrug antibodies  
Characterize the PK/PD of LY3209590   LY3209590 PK and concentration -response 
relationships to key safety and efficacy measures   
Compare the effect of LY3209590 to insulin glargine  
on patient -reported outcomes  questionnaires  Frequency of responses to Basal Insulin Experience of 
“likelihood of incorporating into routine”  
Abbreviations: HbA1c = hemoglobin A1c; DID-EQ = Diabetes Injection Device Experience Questionnaire; 
DTSQ  = Diabetes Treatment Satisfaction Que stionnaire; PK/PD = pharmacokinetics/pharmacodynamics; SMBG 
= self -monitoring of blood glucose; SIM -Q = Simplicity Questionnaire; T2D = type 2 diabetes; TRIM -D = 
Treatment -Related Impact Measure – Diabetes.  
Primary estimand  
[LOCATION_002] registration  
The primary clinical question of interest is  
What is the treatment difference between LY3209590 and insulin glargine  in HbA1c 
change from baseline to Week 52, in study  eligible  participants, regardless of treatment 
discontinuation for any reason and regardless  of initiation of rescue medication?  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744357] is  
What is the treatment difference between LY3209590 and insulin glargine  in HbA1c 
change from baseline to Week 52, in study eligible participants who adhere to the 
randomized treatment without intercurrent events during the study treatment period?  
Efficacy estimand attributes  
This table describes the efficacy estimand attributes.  
Efficacy Regimen Estimand Attribute  Description  
Population  Targeted s tudy population.  See Section 9.[ADDRESS_744358] in change from baseline to Visit 3 3 (Week 52) in HbA1c will also be based 
on the primary estima nds described above.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744359] visit in the treatment period . 
Participants will be random ly assign ed to receive daily insulin glargine or weekly insulin 
LY320959 0.  
Participants random ly assign ed to insulin glargine  
Participants random ly assign ed to insulin glargine will  start on 10  U/day and  will have weekly  
dose adjustments based on FBG and hypoglycemia events (see Section 6.5.2 ). 
Participants random ly assign ed to receive LY3209590  
Participants random ly assign ed to receive LY3209590  will be on a fixed dose escalation for at 
least the first 16 weeks of the study . Participants will  start LY3209590 on a fixed dose of 100  U 
per week  and will  escalate the LY3209590 dose  every 4 weeks  as required  to the set doses of 
150, 250, and 400 U per week . Treat -to-target dose adjustments will be based on  FBG of 80 to 
130 mg/dL  (4.4-7.2 mmol/L)  and hypoglycemia events  (see Section 6.5).  
Dose administration will be via a  fixed  dose autoinjector.   
After Week  16, if a participant who has received  the fixed dose of [ADDRESS_744360]  4 
weeks  has median FBG  levels >130 mg/dL , then the investigator should  transition the participant 
to titratable doses using  a prefilled pen . This  will provide more dosing flexibili ty and allow dose 
titration s above [ADDRESS_744361] continue 
using the prefilled pen for the remainder of the study.  
Screening and Lead -In 
Screening  
Interested participants will sign the appropriate informed consent document(s) prior to initiating 
any procedures.  
The investigator will review medical history, symptoms, risk factors, and other inclusion and 
exclusion criteria prior to any diagnostic procedures. If the participant is eligible after this 
review, then the site will perform the diagnostic procedures to confirm eligibility.  
Lead -In 
Participants will receive their glucometer and electronic study diary and receive training on  
 diabetes self -monitoring and m anagement  
 electronic study diaries, and  
 study requirements.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744362] measure their FBG levels each day when possible or at a 
minimum 3 times per week.  
Participants will continue their current diabetes therapy until randomiza tion. 
Treatment period  
Week s 0-16 (Visits  3-18) 
This is the general flow for Visit 3  
 study personnel confirm enrollment criteria  
 participants are randomly assigned to an intervention group  
 study personnel complete baseline procedures and sample collection  
 study personnel will provide dosing training and the participant receives the first dose of 
LY3209590 or insulin glargine , and  
 study personnel complete all visit procedures.  
Participants assigned to LY3209590 will receive the fixed weekly dose delivered by [CONTACT_566791] , and p articipants assigned to insulin glargine will use daily titratable doses delivered 
by [CONTACT_566792].  Weeks [ADDRESS_744363] 16 doses  for those assigned to LY3209590 .   
See Section 6.5 for detailed dosing information  for LY3209590 and insulin glargine . 
Week 1 (Visit s 4 and 5) 
Visit 4  – telehealth visit  
Study personnel should review FBG and hypoglycemia events from the previous week to  
confirm the appropriate dose.  
For participants assigned to LY3209590, study personnel will confirm the participant administers 
their second dose on that day and the timing of their  second dose .  
Participants should record t he date and time of the  second dose in the e-diary . 
Study personnel will schedule Visit 5 , 3(±1) days after Visit 4 (and the second dose of 
LY3209590 or daily dose of insulin glargine)  in order to collect a PK sample  at the appropriate 
time. A sample will be collected for participants  on LY3209590 and insulin glargine . 
Visit 5  – on-site clinic visit . Note : Visit 5 and Visit 6 cannot be scheduled on the same day.  
Study personnel will complete all visit procedures per t he SoA.   
Week s 16-52 (Visits 1 8-33) 
Participants assigned to LY3209590  will remain on the ir fixed dose  according to the dosing 
instructions in Section  6.5.1 .  
During Weeks 16 -52, if a participant  is receiving  the fixed dose of 400 U/week for at least [ADDRESS_744364]  a median FBG >130 mg/dL for the previous week , the investigator should  
transition the participant to a prefilled pen, which will provide more dosing flexibility  for higher 
doses . See Section 6.5.[ADDRESS_744365] dose at the site.   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744366] study treatment visit: either Week 52  (Visit 3 3) or ED visit  
Assessm ents for the transition to nonstudy diabetic treatment after the participant’s last dose  
The investigator will determine a participant’s transition from study treatment to another 
nonstudy diabetic treatment  (see Section 6.9). 
Participants will continue their concomitant antihyperglycemic medications at the discretion of 
the investigator.  
Safety follow -up visits 801 an d 802  
Study personnel and participants complete all visit procedures described in the SoA.  
The investigator  will follow -up on the participant’s transition from study treatment to another 
nonstudy diabetic treatment  (see Section 6.9). 
Participants will return study devices at the final study visit.  
4.2. Scientific Rationale for Study Design   
Primary endpoint  
The primary efficacy measurement is HbA1c, a widely used measure of glycemic control that 
reflects a cumulative history of glucose levels in the preceding 2 to 3 months.  
Overall design  
Blinding  
This is an open -label study. Investigators, participants, and study -site personnel will be 
unblinded to the assigned treatment. To eliminate potential biases, designated members of the 
Lilly study team will remain blinded throughout the study (see Section 6.3). Only a minimum 
number of Lilly personnel will see the randomization table and treatment assignments before the 
study is complete.  
Study duration  
The treatment duration of [ADDRESS_744367] dose are designed to capture any additional safety signals and 
to monitor the transition from study treatment to nonstudy diabetic treatment.  
Comparator  
Insulin glargine  was chosen as the comparator because it is a widely used basal insulin.  
Collection of race and ethnicity data  
In this study, collection of demographic  information includes ethnicity (where permissible) and 
race. The scientific rationale is based on the need to assess variable response in safety or efficacy 
based on race or ethnicity. This question can be answered only if all the relevant data are 
collec ted.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
41 4.3. Justification for Dose   
The dosing guidance for starting doses and dose modif ications of LY3209590 and insulin 
glargine  are derived based on findings from Phase 2 studies an d PK/PD model -based 
simulations. The uniquely flat PK profile is a key property of LY3209590 . Both modeling -
simulation and the Phase 2 results support no need for  frequent  dose adjustments with a low risk 
of hypoglycemia in insulin -naive T2D.   
These data informed the development of a treat-to-target  dose escalation scheme using 4 fixed 
doses of 100 U, 150  U, 250  U and 400  U, to safely and efficiently initiate and guide LY3209590 
dose adjustments to achieve the glycemic goals of FBG between 80 an d 130 mg/dL, while 
minimizing hypoglycemia risk.  
The potential benefits  of the fixed dose escalation  regimen administered by [CONTACT_566793]  
 the ease of use for people  nervous about starting injection therapy , and  
 a viable  first step in overcom ing insulin initiation and  titration inertia  for people with 
T2D who are starting basal insulin for the first time.  
LY3209590 starting dose  
To determine the appropriate starting  dose for the autoinjector , simulation s were performed 
using a wide range of starting doses . A starting dose of  100 U was selected because i t showed  
similar or lower hypoglycemia rates compared to insulin degludec  and resulted in a very low 
drop-out rate as a result of hypoglycemia (<5%).  Importantly, this starting dose is consiste nt with 
the actual average mean weekly starting dose of ~ [ADDRESS_744368] scheduled procedure shown in the SoA . 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
42 5. Study Population   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers  or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Are ≥ [ADDRESS_744369] an HbA1c of 7.0%  to 10.0%, inclusive, determined by  [CONTACT_221037].  
4. Are on a stable treatment with 1 to 3 antihyperglycemic medication(s) for at least [ADDRESS_744370] label.  
Up to 3 of these antihyperglycemic medications are acceptable  
 DPP-4 inhibitors  
 SGLT2 inhibitors  
 biguanides, such as metformin  
 alpha -glucosidase inhibitors  
 GLP -[ADDRESS_744371] able, or 
 thiazolidinediones.  
5. Are insulin naïve.  
Exceptions:  
 short -term insulin treatment for a maximum of 14 days, prior to screening, and  
 prior insulin treatment for gestational diabetes.  
Weight  
6. Have a body mass index ≤45  kg/m2. 
Contraceptive or barrier requirements  
Contraceptive use by [CONTACT_51981].  
7. Male participants: no male contraception required except in compliance with speci fic 
local government requirements.  
Female participants: for the contraception requirements of this protocol, see Section 10.4. 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
43 Study procedures  
8. Are reliable and willing to make themselves available for the duration of the study and 
are willing and able to follow study procedures as required, such as  
 self-inject inte rvention  
 store and take provided study interventions as directed  
 maintain an electronic study diary , and  
 use only the gluco se monitoring device  supplied for use in the study . 
Note  a): persons with physical limitations who are not able to perform the inject ions must 
have the assistance of an individual trained to inject the intervention.  
Note  b): The use of personal  glucometer or continuous glucose monitoring  device is not 
permitted.  
Informed consent  
9. Are capable of giving signed informed consent as described  in Section 10.1.[ADDRESS_744372] 
a usual sleepi[INVESTIGATOR_136677].  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical conditions  
11. Have a diagnosis of T1D, latent autoimmune diabetes, or specific type of diabetes other 
than T2D, for example, monogenic diabetes, diseases of the exocrine pancreas, or drug -
induced or chemical -induced diabetes.  
12. Have a history of >[ADDRESS_744373] an 
estimated glomerular filtration rate <20  mL/min/1.[ADDRESS_744374] had [LOCATION_001] Heart Association Class IV heart failure or any of these 
cardiovascular  conditions within 3 months prior to screening  
 acute myocardial infarction  
 cerebrovascular accident (stroke), or  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
44  coronary by[CONTACT_4897].  
18. Have had gastric by[CONTACT_6476] (bariatric) surgery, restrictive bariatric surgery, for example Lap -
Band, or sleeve gastrectom y within [ADDRESS_744375] had a significant weight gain or loss within 3 months prior to screening, for 
example, ≥5%. 
20. Have acute or chronic hepatitis, cirrhosis, or obvious clinical signs or symptoms of any 
other liver disease  (except nonalc oholic fatty liver disease , which is allowed) , or have 
elevated liver enzyme measurements , determined by [CONTACT_51983] , 
of the following  
 total bilirubin >2x ULN , except for participants previously diagnosed with 
Gilbert’s syndrome  
 ALT  or serum glutamic pyruvic transaminase > 3x ULN  
 AST or serum glutamic oxaloacetic transaminase > 3x ULN, or  
 ALP >2.5x ULN.   
21. Have a history of an active or untreated malignancy or are in remission from a clinically 
significant malignancy within 5 years prior  to screening.  
Exception:  Basal cell or squamous cell skin cancer.  
22. Are at increased risk for developi[INVESTIGATOR_51944] a recurrence of cancer.  
23. Have a history of or current significant psychiatric disorders considered clinically 
significant, in the opi[INVESTIGATOR_8598] e investigator.  
24. Have a history or presence of an underlying disease, or surgical, physical, or medical 
condition that, in the opi[INVESTIGATOR_871], would potentially affect participant 
safety within the study or interfere with the interpretation of data.  
25.  Have a known hypersensitivity or allergy to any of the study interventions or their 
excipi[INVESTIGATOR_840].  
Prior or concomitant therapy  
26. Have received these diabetes treatments within 30 days prior to screening  
 glinides  
 pramlintide  
 sulphonylureas  
 Dual GIP/GLP -1 RA ( for example,  tirzepatide) , or 
 insulin or any insulin containing product.  
27. Are receiving or received systemic glucocorticoid therapy for >14 days within the month 
before screening.  
Exceptions:  
 replacement therapy for adrenal insufficiency  
 topi[INVESTIGATOR_2855], intra ocular, intranasal, or inhaled preparations, or  
 intra-articular injection.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744376] evidence of any substance use disorder of any severity defined by [CONTACT_51984] -5, within 6 months prior to screening.  
Exception: nicotine or caffeine.  
34. Are Lilly employees or are employees of any third party involved in the study who 
require exclusion of their employees.  
35. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.  
36. Are unsuitable for inclusion in the study in the opi[INVESTIGATOR_871].  
5.3. Lifestyle Considerations   
Diabetes management counseling  
Qualified study personnel will provide diabetes management counseling, which will include 
instructions on diet and exercise and education about the signs, symptoms, and treatment of 
hypoglycemia, should it occur. Diabetes self -management counseling may be reviewed 
throughout the study, as needed.  
Dietary and exercise considerations  
Study participants should generally follow a healthy meal plan and continue their usual exercise 
habits throughout the course of the study.  
Dietary and exercise restrictions  
Study particip ants should not initiate an intensive diet or exercise program with the intent of 
reducing body weight at any time during the study, other than the lifestyle and dietary measures 
for diabetes treatment.  
Blood donation  
Study participants should not donate b lood or blood products during the study or for [ADDRESS_744377] study visit.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
46 5.4. Screen Failures   
A screen failure occurs when a participant  who consent s to participate in  the clinical study  is not 
subsequently randomly assigned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participant s to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any SAE .  
Individuals who do not meet the criteria for participation in this  study (screen failure) will not be 
rescreened.  
5.5. Criteria for Temporarily Delaying Enrollment of a Participant   
This section is not applicable to this study. All entry criteria mu st be met within the specified 
intervals in the SoA.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
47 6. Study Intervention (s) and Concomitant Therapy   
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.   
Investigators and other study personnel are expected to treat participants according to the 
nationally established standa rds of care for diabetes management in respective participating 
countries, except where that treatment would be in conflict with the protocol -provided treatment 
requirements. If there are no local or national standards of care for diabetes, the investigato rs 
should follow current published standards of care from the American Diabetes Association.   
6.1. Study Intervention(s) Administered   
LY3209590 and insulin glargine  will be dispensed at the study visits summarized in SoA.  
Returned LY3209590 or insulin glargine  should not be re -dispensed to the participants.  
This table lists the interventions used in this clinical study.  
Intervention 
Name  [CONTACT_36940]3209590  Insulin glargine  
Dose 
Formulation  Solution  Solution  
Unit Dose 
Strength(s)  
 Autoinjector  fixed dose  
strengths  
 100 U/0.5 mL 
 150 U/0.5 mL 
 250 U/0.5 mL 
 400 U/0.5 mL Prefilled pen for variable 
doses (>400 U)  
500 U/mL  Prefilled pen  
100 U/mL  
Dosage Level(s)  Individualized dosing  
(see Section 6.5.1 ) Individualized dosing  
(see Section 6.5.2 ) 
Frequency of 
Administration  Once weekly   Once daily  
Route of 
Administration  Subcutaneous  Subcutaneous  
Authorized as 
defined by [CONTACT_566794] 
a Study interventions identified as authorized are used in accordance with the terms of their marketing 
authorizations.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744378] the sponsor . 
Insulin glargine dosing information  
See Section 6.5.1  for dose initiation and guidance for dose adjustments.  
Insulin glargine frequency of administration  
Insulin glargine should be administered daily at approximately the same time each day.  
Anatomical location of injections  
Acceptable locations for injection include the a bdomen, thigh, arm , or buttock.   
For both LY3209590 and insulin glargine , participants should rotate injection sites from one 
injection to the next, even when injecting with in the same region.  
Packaging and labeling  
Study interventions will be supplied by [CONTACT_489927]. Study interventions will be labeled as appropriate for country 
requirements.  
6.1.1.  Medical Devi ces  
LY3209590 will be provided as a drug/device combination product with either a  single  dose 
autoinjector  or a prefilled pen for the administration of LY3209590.  All participant s random ly 
assign ed to receive LY3209590 will use autoinjectors for at least the first 1 5 weeks of the study  
but may transition to a prefilled pen if doses >400 U per week are required from Week 16 
onwards.   
Insulin glargine  will be provided  as a solution  in a prefilled pen . 
Instructions for device will be  provided.  
All PCs or device deficiencies , including malfunction, use error and inadequate labeling, shall be 
documented and reported by [CONTACT_31819] (see 
Section  8.3.1 ) and appropriately managed by [CONTACT_456].   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
49 6.1.2.  Rescue Medicine for Management of Severe or Persistent Hyperglycemia   
The investigator should follow this general guidance if a participant develops severe, persistent 
hyperglycemia during the study . 
If a participant develops severe, persistent hy perglycemia after Week 16, additional 
antihyperglycemic medication should be considered after investigator assessment, based on 
conditions described in this table.  
Average of fasting blood glucose over 2 -week period  Timing of events  
>270  mg/dL (15  mmol/L)  Weeks 16 to 20  
(from Visit 18 until Visit 22)  
>240  mg/dL (13  mmol/L)  Weeks 20 to 26  
(after Visit 22 until Visit  25) 
>200  mg/dL (11  mmol/L)  Weeks 26 to 52  
(after Visit 25 until Visit 33) 
Note: Rescue medicine may start at Week 12 in the rare instanc e that a participant had a dose reduction due to 
hypoglycemia but subsequently has severe or persistent hyperglycemia and meets the average of FBG 
>200  mg/dL over a 2-week period.  
Before changing the dose of concomitant medications or introducing any new treatments as 
rescue therapy , investigators should first confirm participant  compliance with the assigned 
intervention , LY3209590 or insulin glargine,  and ensure that the  participant  does not have an 
acute condition causing severe hyperglycemia.  
Next, inve stigators should optimize the participant’s concomitant antihyperglycemic medications 
or consider the addition of allowed concomitant antihyperglycemic medications (see Section 
6.8.3 ), if applicable, so the participant is taking up to 3 antihyperglycemic medications at 
effective doses before considering rescue therapy with insulin. Investigators should report any 
changes in dose for the concomitant ant ihyperglycemic medications that are in response to 
meeting the rescue criteria, as rescue therapy in the CRF.  
The investigator should ensure that the participant met the criteria for severe or persistent 
hyperglycemia before initiating rescue medicine and document this in the source files.  
If severe, persistent hyperglycemia is not improving despi[INVESTIGATOR_566782] -lowering agents, the addition 
of prandial insulin may be conside red.  
Participants who receive rescue therapy for hyperglycemia management should also continue 
administering  either LY3209590 or insulin glargine for the remaining period in the study.    
If a participant  is transitioning to a prefilled pen , investigators should  
 ensure that the transition does not occur at the same time as initiation of rescue therapy , 
and  
 wait for at least [ADDRESS_744379] dose with the LY3209590 prefilled pen.   
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744380] be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized  study personnel . 
The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, reconciliation, and final 
disposition records).  
Further guidance and information for the final disposition of unused study interventions are 
provi ded in the Pharmacy  Manual.   
Participant responsibilities  
In-use storage conditions are expected to be followed according to the instructions for use 
provided by [CONTACT_456]. Study participants will be trained on the proper storage and handling of 
the stud y intervention.   
6.3. Measures to Minimize Bias: Randomization and Blinding   
Randomization and stratification  
All participants will be centrally assigned to randomized study interventi on using an IWRS. 
Before the study is initiated, the login information and directions for the IWRS will be provided 
to each site.  
Participants will be randomly assigned in an 1:1 ratio to LY3209590:insulin glargine.  
Participants will be stratified based on  
 country  
 HbA1c stratum at Visit 1 (<8% and ≥8% ), and   
 GLP -1 RA use at randomization, regardless of oral or injectable administration , 
(Yes/No) . 
Blinding  
This is an open -label study. Investigators and participants will be unblinded to the assigned 
treatment  groups.  
The Lilly study team members who are closely involved in data interpretation and analysis 
planning will remain blinded throughout the course of the study. Only a minimum number of 
Lilly personnel will see the randomization table and treatment assi gnments before the study is 
complete.  
The investigator should make every effort to preserve the blinding  when contact[CONTACT_51986], including the Lilly clinical research physician or scientist.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
51 Unblinded reviews  
External committees reviewing unblinded data during the study are described in Section 10.1.5 . 
An early PK/PD unblinded transfer may also be conducted . Only a small group of personnel can be 
unblinded to the data for the potential PK/PD analysis and must keep information confidential until 
the planned unblinding of the trial.  
6.4. Study Intervention Compliance   
Participants are responsible for entering the date of their daily or weekly insulin dose and dose 
amount in their e -diary.  
The investigator or trained designee will assess treatment compliance at each visit based on 
review of the participant glycemic control, e -diary completion, and adherence to prescribed dose 
and study procedures.  
If a participant is considered poorly compliant with their study procedures, for example, missed 
visits or specific diagnostic tests, they will be retrained as needed by [CONTACT_51015].   
6.5. Dose Modification   
The investigator is responsible for titrating the basal insulin dose using the guidance in the SoA , 
Sections 6.5.1  and 6.5.2  and their clini cal judgment.  
General insulin dose adjustment considerations  
Fasting blood glucose   
Dosing will be individualized based on FBG and hypoglycemia events.  
The FBG treat -to-target is 80 to 130  mg/dL (4.4 to 7.2  mmol/L), inclusive.   
Use the median FBG for dose adjustment  and follow th is guidance : 
 Determine the median FBG from the [ADDRESS_744381] recently recorded FBG readings from the 7-
day period  prior to the site visit.   
 If only 2 FBG measurements are available, use the lower of the readings for the dose 
assessme nt. 
 If only 1 FBG measurement is available, the investigator determin es if a dose change  is 
necessary .  
Investigators are expected to follow the dosing regimen  for the protocol . However, modifications 
of the basal insulin dose may be influenced by [CONTACT_566795]. If the investigator prescribes a dose other than the 
regimen  recommended dose, the investigator is respons ible for documenting the clinical rationale 
for the prescribed dose . 
When considering any dose adjustments (in either treatment group), the investigator will also 
review whether the participant experienced any documented epi[INVESTIGATOR_17221]. If the 
participant experienced any documented BG ≤70 mg/dL (≤3.9 mmol/L) in the previous week, 
the basal insulin dose should not be increased.  
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
52 Hypoglycemia  
A participant’s dose may be decreased based on hypoglycemia at any time during the study  
(Sections 6.5.1  and 6.5.2 ). 
Do not increase the s tudy intervention dose if hypoglycemia (BG ≤70 mg/ dL) is reported in the 
week prior to the assessment.  
Although hypoglycemia criteria for dose reduction are specified in the tables for each treatment 
in Sections 6.5.1  and 6.5.2 , it is important for the investigator to rule out any other contributing 
factors , such as  increased physical activity or illness , which may caus e an unusual occurrence of 
hypoglycemia. In the se circumstances, the decision to reduce the dose is at the discretion of the 
investigator.   
Study participants will be instructed to check their BG, when they experience signs and 
symptoms suggestive of hypoglycemia, and to administer appropriate treatmen t for when BG 
≤70 mg/dL (3.9 mmol/L). They will be instructed to recheck BG levels 15 minutes following 
treatment of hypoglycemia and repeat treatment and BG recheck after another 15 minutes until 
the BG level has returned to the target range of 80 -130 mg/ dL (4.4 -6.6 mmol/L) (CDC 2021). 
Instructions will be provided for clinical management of participants who experience frequent or 
repeated hypoglycemia. As necessary, additional instruction/education may be provided to 
participants by [CONTACT_566796], i ncluding increased BG monitoring, treatment adjustments, or 
other approaches (for example, behavioral interventions and lifestyle modification) to mitigate 
hypoglycemia frequency or severity.  
6.5.1.  LY3209590 Dose Initiation and Adjustment   
This section outlines the LY3209590  
 general dosing information  
 dose adjustments guidance based on FBG, and  
 dose adjustment guidance based on hypoglycemia . 
[IP_ADDRESS].  General LY3209590 Dosing Information   
Starting dose  
The starting dose for LY3209590 occurs on Week 0 at Visit 3 , and  is 100 U , administered once -
weekly , using a single dose autoinjector.  
Dose escalations for Week 4 up to Week 16 (Visits 8-18)  
The investigator should make every effort to follow the fixed  dose escalation regimen  to achieve 
a treat -to-target FBG of 80  to130 mg/dL during the first 16 weeks using the fixed dose levels of 
150 U, 250 U, and 400 U , administered once -weekly by [CONTACT_566797] s.  
Assessments for potential dose adjustment will occur every 4 weeks based on a participant’s 
median FBG and hypoglycemia events.  
Participants will maintain a dose level for 4 weeks until the next ass essment for potential dose 
increase.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744382] every 4 weeks .  
If a participant  has a fixed dose (autoinjector) escalation after Week [ADDRESS_744383] remain on that 
dose for 4 weeks before an assessment for further dose e scalation . 
If, at Week 16 or after, a participant…  Then…  
 has been on the fixed dose of 400 U/week for at 
least 4 weeks  
 has a  median FBG >130 mg/dL for the previous 
week, A ND 
 has not met hypoglycemia criteria described in 
Section [IP_ADDRESS] . the investigator should transition the participant to a 
variable dose delivered by [CONTACT_566798].  
Note:  The prefilled pen provides more dosing 
flexibility and allows dose titration above 400 U/week.  
If a participant transitions from the fixed dose a utoinjector to the prefilled pen, the first dose 
administration with the prefilled pen will be administered at the site.  
If a participant transitions from the fixed  dose autoinjector to a prefilled pen, they must continue 
using the prefilled pen for the r emainder of the study.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
54  
LY3209590 dose escal ation schema  
 
Abbreviations:  AI = autoinjector; FBG = fasting blood glucose ; U = units.  
1At [ADDRESS_744384] remain on the autoinjector dose for 4 weeks before next assessment for dose escalation.  
380-130 mg/dL.  
4Participants who transition to the prefilled pen must continue to use this device for the remainder of the study.  
 
Details for dose reduction in response to hypoglyce mia ar e given in Section [IP_ADDRESS] . 
 
  
Scheduled FBG 
assessment for 
dose escalation1,2Remain on current 
AI doseAt target FBG3
Above target FBG3
Reassess after 4 wks
Received 400 U/ wkfor ≥ 4 
wks and above target FBG3
Start dose 
100 U AI
Dose increase to  
next step up 150 U, 
250 U or 400 U AI
Transition to 
Prefilled pen for 
doses > 400 U/wk4Wks 0-16 and per visit 
schedule thereafter
Wks 16-52
Received 400 U/ wkfor ≥4 
wks and at target FBG3
Scheduled FBG 
assessment for 
dose escalation1,2At target FBG3
Above target FBG3Remain on 400 U 
AI 
Flexible doses 
adjusted per protocol
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
55 [IP_ADDRESS].  LY3209590 Dose Adjustments Based on Fasting Blood Glucose   
Dose adjustments for participants on a fixed dose  administered by [CONTACT_566799] 4 week s. 
This table provides guidan ce for dose adjustments if the participant is on a fixed dose 
administered by a single dose autoinjector.   
If the median FBG is…  And…  Then…  
<80 mg/dL  <4.4 mmol/L  the participant has not 
met hypoglycemia 
criteria described in 
Section [IP_ADDRESS]   do not change the dose.  
 make recommendations to the participant to 
reduce hypoglycemia risk or occurrence , for 
example   
o  more frequent  BG monitoring   
o  consider behavioral interventions and 
lifestyle modifications . 
80-130 mg/dL 
(target)  4.4-7.2 
mmol/L  ---- do not change the dose.  
>130  mg/dL  >7.3 mmol/L  ---- increase the LY3209590 dose to the next higher 
single dose autoinjector dose level.  
>130 mg/dL at or 
after Week 16  >7.3 mmol/L 
at or after 
Week 16  the participant  
 has been on a fixed 
dose of 400 U/week 
for at least 4 weeks, 
and  
 has not met 
hypoglycemia 
criteria described in 
Section [IP_ADDRESS] . the investigator should transition the participant 
to a prefilled pen with variable dose capabilities 
above 400  U/week.  
Dose adjustment for participants on a variable dose administered by a  prefilled pen  
If a participant transitions from the single dose autoinjector to a prefilled pen, they must continue 
using the prefilled pen for the remainder of the study.  
Assessments for potential dose adjustment may occur weekly or at least every 4 week s. 
This table provides guidance for dose adjustments if the participant is transitioning to or using 
the prefilled pen.  
If the median FBG is…  Then…  
<80 mg/dL  <4.4 mmol/L  reduce the LY3209590 dose by 20  U. 
80-130 mg/dL  (target)  4.4-7.2 mmol/L  do not change the dose.  
131-140 mg/dL  7.3-7.7 mmol/L  increase the LY3209590 dose by 20  U. 
>140  mg/dL  >7.7 mmol/L  increase the LY3209590 dose by 40  U. 
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
56 [IP_ADDRESS].  LY3209590 Dose Adjustments Based on Hypoglycemia Events   
Guidance for participants receiving 100 U LY3209590  
If a participant is receiving a 100 U LY3209590 dose and experiences hypoglycemia, the 
investigator will  
 rule out any other contributing factors, such as increased physical activity or illness, 
which may cause an unusual occurrence of hypoglycemia, and  
 discontinue intervention  if participant meets dose reduction criteria due to hypoglycemia . 
General guidance  
If a participant experiences any hypoglycemia event  (BG ≤70 mg/dL)  in the previous  week and 
their FBG  is >130 mg/dL at the next dose assessment time  point, the investigator should not 
increase the dose. In this situation, the only time the investigator should increase the dose is if 
they determine that it was an unusual occurrence of hypoglycemia that was explained by [CONTACT_566800], such as increased physical activity or illness.  
Dose adjustments for participants on a fixed dose administered by [CONTACT_566801].  
If a participant using the 
autoinjector reports…  With a blood glucose value of...  Then…  
≥3 hypoglycemic events  ≤70 mg/dL (3.9  mmol/L)  
reduce the LY3209590 dose to the 
next lower autoinjector dose level.  ≥1 hypoglycemic event  <54 mg/dL (3.0  mmol/L)  
≥1 nocturnal hypoglycemic event  ≤70 mg/dL (3.9  mmol/L)  
any confirmed severe hypoglycemia  
(neurological impairment confirmed 
by [CONTACT_1697])  ___ 
If the autoinjector dose is reduced due to hypoglycemia, the participant should remain on the 
lower dose for the remainder of the study, unless a further dose decrease is required due to 
hypoglycemia.   
Dose adjustment for participants on a variable dose a dministered by a prefilled pen  
This table provides guidance for dose adjustments based on hypoglycemia events.  
If a participant using a prefilled 
pen reports…  with a blood glucose value of...  then…  
≥3 hypoglycemic events  ≤70 mg/dL (3.9  mmol/L)  
reduce the  LY3209590 dose by 40  U. ≥1 hypoglycemic event  <54 mg/dL (3.0  mmol/L)  
≥1 nocturnal hypoglycemic event  ≤70 mg/dL (3.9  mmol/L)  
Any confirmed severe 
hypoglycemia  
(neurological impairment confirmed 
by [CONTACT_1697])  ___ 
6.5.2.  Insulin Glargine  Dose Initiation and Adjustment   
This section outlines the insulin glargine  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
57  general dosing information  
 dose adjustment guidance based on FBG, and  
 dose adjustment guidance based on hypoglycemia.  
[IP_ADDRESS].  General Insulin Glargine Dosing Information   
All insulin glargine doses will be administered using a prefilled pen.  
The starting dose for insulin glargine occurs  on Week 0 at Visit 3.  
The starting dose for insulin glargine is 10 U/day.   
The investigator will use an individualized flexible dose approach throughout the study with 
weekly assessments for potential dose adjustment during the 52 weeks of treatment.   
[IP_ADDRESS].  Insulin Glargine Dose Adjustments According to Fasting Blood Glucose   
This table provides guidance for dose adjustments based on median FBG recorded during the 
previous week.  
If the median FBG is…  Then…  
<80 mg/dL  <4.4 mmol/L  reduce the dose by 3  U. 
80-130 mg/dL  (target)  4.4-7.2 mmol/L  do not change the dose.  
131-140 mg/dL  7.3-7.7 mmol/L  increase the dose by 3  U. 
>140 mg/dL  >7.7 mmol/L  increase the dose by 6  U. 
[IP_ADDRESS].  Insulin Glargine Dose Adjustments According to Hypoglycemia Events   
A participant’s dose may be decreased based on hypoglycemia at any time during the study.  
Dose adjustments for participants receiving insulin glargine  
This table provides guidance for dose adjustments based on hypoglycemia events.  
If a participant reports…  With a blood glucose value 
of… Then…  
≥3 hypoglycemic events  ≤70 mg/dL (3.9  mmol/L)  reduce the dose by 2 to 6 U. 
 
Dose reductions of 2 or 4 U may 
occur every 3 days to achieve a 
weekly 6  U reduction as clinically 
indicated.  ≥1 hypoglycemic event  <54 mg/dL (3.0  mmol/L)  
≥1 nocturnal hypoglycemic event  ≤70 mg/dL (3.9  mmol/L)  
any confirmed severe hypoglycemia 
(neurological impairment confirmed by 
[CONTACT_1697])  ___ 
 
6.6. Continued Access to Study Intervention after the End of the Study   
The sponsor will not provide participants with any ongoing supplies of study intervention after 
they have completed the study treatment period or permanently discontinued the study 
intervention.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744385] label for insulin glargine  depending on 
the participant treatment assignment.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
59 In the event of an overdose, the investigator  or treating physician should:  
 contact [CONTACT_10990]  
 consider holding non -insulin diabetes medications, if clinically appropriate  
 evaluate the participant to determine, in consultation with the medical 
monitor, whether study intervention shou ld be interrupted or whether the dose 
should be reduced  
 closely monitor the participant for any AE or SAE and laboratory abnormality 
until study intervention no longer has a clinical effect, and  
 obtain a plasma sample for PK analysis if the participant is assigned to 
LY3209590 . 
 
6.8. Concomitant Therapy   
Concomitant therapy regimens  
All participants should maintain their usual medication regimens for concomitant conditions or 
diseases throughout the study, unless those medications are specifically excluded in the protocol 
(see Section 5.2). 
Participants taking concomitant medications should be on stable dosages at the time of screening 
and should remain at stable dosages throughout the study, unless changes need to be made 
because of an AE or rescue therapy (see Section 6.1.2 ). 
Acceptable non -insulin diabetes treatments are described in Section  6.8.3 . 
Changin g concomitant therapy  
Participants should consult with authorized study personnel before taking any new medications 
during the study, except when initiated for treatment of medical emergencies. Authorized study 
personnel should consult the sponsor’s medica l monitor if there are any questions about 
concomitant therapi[INVESTIGATOR_226].  
Concomitant therapy data collection  
For therapy that the participant is receiving at the time of enrollment or receives during the 
study, including over -the-counter medicati ons, authorized study personnel should collect  
 the name [CONTACT_2100], vaccine, or therapy  
 the reason for use, and  
 dates of administration, including start and end dates.  
For diabetes and lipid -modifying medications, collect  dosage information including do se and 
frequency.  
Nonstudy medications taken by [CONTACT_51991], but are not 
randomly assigned, will not be reported unless an SAE or AE occurs that the investigator believes 
may have been caused by a study procedure.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
60 6.8.1.  Medications with Approved Weight Loss Indication   
Allowed usage of weight loss medication during the study  
A participant may use a medication that promotes weight loss if they are  on stable therapy 90 
days prior to screening.  
Allowed medications include, but are not limited to  
 over-the-counter medications, including food supplements that promote weight loss  
 liraglutide 3.0 mg  
 orlistat  
 sibutramine  
 mazindol  
 phentermine  
 lorcaserin  
 phentermine and topi[INVESTIGATOR_81063]  
 naltrexone or bupropi[INVESTIGATOR_2394], or  
 semaglutide injection  2.[ADDRESS_744386] 30 days apart.  
This restriction does not apply to glucocorticoid therapy used as replacement therapy for adrenal 
insufficiency, or topi[INVESTIGATOR_2855], intraocular, intranasal, inhaled preparations, and int ra-articular  
injections . 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
61 6.8.3.  Antihyperglycemic Medications   
This table shows the conditions for use of concomitant antihyperglycemic medications.  
Drug Class  Use during Screening or 
Lead -In Conditions for Use after Randomization  
 Y = yes, if on stable therapy 
90 days prior to screening.  
N = No During 
Treatment 
Period  Acute 
Therapy  
Treatment 
for up to 14 
days  Rescue 
Therapy  During 
Safety 
Follow -
Up 
Period  
GLP -1 RAs  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
DPP-4 inhibitors  Y N/A Y Y 
SGLT2 inhibitors  Y N/A Y Y 
Nonstudy basal 
insulins  N N Yes, only if 
study basal 
insulin is 
temporarily 
discontinued  See Note  Y 
Insulin mixtures  N N Yes, only if 
study basal 
insulin is 
discontinued  See Note  Y 
Prandial insulin  N N Y Y Y 
Meglitinides  N N N/A N Y 
Dual GIP/GLP -1 RA s 
(for example,  
tirzepatide)  N N N/A N Y 
Alpha -glucosidase 
inhibitors  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
Sulfonylureas  N N N/A N Y 
Thiazolidinediones  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
Metformin a Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Yes, if the 
dose is below 
maximum 
approved dose 
per country -
specific label  Y 
Abbreviations: DPP -4 = dipeptidyl peptidase -4; GIP = glucose dependent insulinotropic peptide; GLP -1 RA = 
glucagon -like peptide -[ADDRESS_744387]; N = no; N/A   not applicable; SGLT2 = sodium -glucose cotransporter 2; Y 
= yes.  
a Switching metformin manufac turer is allowed if the dosage is the same. Changing to a metformin formulation with 
a different action profile (that is, from short -acting to long -acting metformin) is not permitted.   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
62 Note:  Participants who require a nonstudy basal insulin or insulin mixt ure as rescue therapy must first discontinue 
study intervention  (LY3209590 or insulin glargine). The participant will remain in the study and follow procedures 
for the remaining study visits . 
Dose adjustments of allowable non-insulin antihyperglycemic medi cations  are permitted after 
randomization under the following circumstances : 
 situations that require short -term treatment interruption consistent with the product 
labeling for each respective country  
 situations that require dose adjustment or discontinuati on per country -specific label, for 
example, in the case of reduced estimated glomerular filtration rate  
 in the case of increased hypoglycemia risk during the treatment period (as described in 
Section 8.3.6 ) 
 a dose increases as part of rescue therapy, and  
 for safety reasons at the discretion of the investigator.  
Any changes in dose should be documented.   
6.9. Nonstudy Treatment  after the End of the Study   
The investigator will assess each  participant  to determine the need to transi tion to a nonstudy 
treatment for T2D  at visits described in the SoA.  Unscheduled visits, in addition to those 
described  in the SoA , may occur during this time to facilitate the transition.  
The participant’s FBG and other clinical factors should be used to guide dose initiation and 
adjustment  in accordance with the country -specific label .  
A daily basal insulin is not  required until the FBG is above 120  mg/dL for 2 consecutive 
measurements.  
If a nonstudy daily basal insulin is required, start the dose  at 10 U/day and adjust based on FBG 
and investigator judgment in accordance with any country -specific label.  
Study participants treated with LY3209590  
Since LY3209590 has a half -life of approximately 17 days, a careful titration of any new anti-
hyperglycemic tre atment  will be  necessary to prevent hypoglycemia due to overlappi[INVESTIGATOR_79730]. 
The investigator should consider titrating the daily insulin to reach 50% of the required daily 
dose at approximately 2  weeks and 80% at approximately 4  weeks.  
Study participants treated with insulin glargine  
Study participants assigned to insulin glargine  will transition to a nonstudy treatment  after Visit 
33. The investigator will prescribe the nonstudy treatment and titrate the dose based on their 
clinical judgment i n accordance with the country -specific label.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
63 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal   
Discontinuation of specific sites or of the study as a whole are handled as part of Section 10.1.9 . 
7.1. Discontinuation of Study Intervention   
When  necessary , a participant may be permanently discontinue d from  study i ntervention. If so, 
the participant will remain in the study and follow procedures for remaining study visits , as 
shown in the SoA .  
Participants who stop the study intervention permanently may receive another glucose -lowering 
medication. The new glucose -lowering medication will be recorded on the CRF for 
antihyperglycemic medications.  
A participant should be permanently discontinued from study intervention if  
 the participant becomes pregnant during the study  
 the participant requests to discontinue study in tervention  
 the participant is receiving a 100  U dose and needs a dose reduction  
 the participant is diagnosed with an active or untreated malignancy, except for 
successfully treated basal or squamous cell carcinoma  
 the participant did not take insulin glargine  for more than 21 consecutive days or 
missed more than 3 consecutive doses of LY3209590 at any time during the study, or  
 in the opi[INVESTIGATOR_871], the participant should permanently discontinue the 
study intervention for safety reasons.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744388] >8x ULN   
ALT or AST >5x ULN for more than [ADDRESS_744389] >3x ULN and either TBL >2x ULN or INR >1.5  In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for intervention interruption or 
discontinuation decisions rather than TBL 
>2x ULN.  
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3x ULN, when the source of increased ALP is the liver   
ALP >2.[ADDRESS_744390] and TBL >2x ULN  In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for intervention interruption or 
discontinuation decisions rather than TBL 
>2x ULN.  
ALP >2.5x ULN with the appearance of fatigue, nausea, vomiting,  
right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)   
Resumption of the study intervention can be considered only in consultation with the 
Lilly -designated medical monitor and only if the liver test results return to baseline and if a 
self-limited, non -intervention etiology is identified.  
7.1.2.  Hypersensitivity Reactions   
If the investigator determines that a systemic hypersensitivity reaction has occurred r elated to 
study intervention administration, the participant may be permanently discontinued  from the 
study intervention, and the sponsor’s designated medical monitor should be notified.  
If the investigator is uncertain about whether a systemic hypersensit ivity reaction has occurred 
and whether discontinuation of study intervention is warranted, the investigator may consult the 
sponsor.   
7.1.3.  Temporary Discontinuation  of Study Intervention   
Criteria for temporary discontinuation of LY3209590 or insulin glargine  
The investigator may temporarily interrupt study treatment, due to an AE, clinically significant 
laboratory value, hospi[INVESTIGATOR_6042], travel, or shortage of study treatment supply.  
This will be allowed for up to 21 consecutive days for insulin glargine  or 3 consecutive doses for 
LY3209590 at any time during the study. This information should be documented by [CONTACT_1275].  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744391] be docum ented in source documents 
and entered on the CRF . 
Participant  noncompliance should not be recorded as interruption of study intervention  on the 
CRF .  
7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study  
 at any time at the participant’s  own request  
 at the request of the participant’s  designee ( for example, parents or legal 
guardian)  
 at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
 if the participant is diagnosed with any type of diabetes mellitus other than 
T2D  
 if enrolled in any other clinical  study involving an investigational product , or 
enrolled in any other type of medical research judged not to be scientifically 
or medically compatible with this study , or 
 if the participant , for any reason, requires treatment with a therapeutic agent 
that is prohibited by [CONTACT_566802] . In this case , discontinuation from the 
study occurs prior to introduction of the new agent . 
At the time of discontinuing from the study, if possible,  the participant will complete  procedures 
for an early discontinuation visit and post -treatment follow -up, as shown in the SoA.  
If the participant has not already discontinued the study intervention, the participant will be 
permanently discontinu ed from the study intervention at the time of the decision to discontinue 
the study.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consen t.  
If a participant  withdraws from the study, the participant  may request destruction of any samples 
taken and not tested , and the investigator must document this in the site study records . 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744392] participants who fail to return for a scheduled visit or were 
otherwise unable to be followed up by [CONTACT_779].   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744393] reasons for sc reening failure, as 
applicable.   
8.1. Efficacy Assessments   
Efficacy wi ll be measured by  
 HbA1c  
 FBG   
 insulin dose, and  
 patient -reported outcomes questionnaires  
o TRIM -D 
o DTSQ -status  
o DTSQ -change  
o SIM-Q 
o DID-EQ, and  
o Basal Insulin Experience.  
See Section [ADDRESS_744394]  use only the study -provided glucometer during the study.  The use of personal 
glucometer or continuous glucose monitoring is not permitted.  
[IP_ADDRESS].  Self-Monitoring of Blood Glucose (SMBG)   
Glucometer for participant use during the study  
Participants will receive a sponsor -approved glucometer and related testing supplies for use 
during the study.  
Site personnel will train the participant on correct use of the glucometer for self -monitoring 
blood glucose and reporting of hypoglyce mia data in the e -diary.  
Participants should use the glucometer  
 for the 6 -point profile  
 whenever hypoglycemia is experienced or suspected  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
68  Note: If BG values are <80 mg/dL but not below <70 mg/dL ( that is , defined as 
hypoglycemia), recommend to the participant that they monitor their BG more frequently to 
prevent hypoglycemia. This is particularly relevant to participants receiving LY3209590 via 
the autoinjector, where dose cannot  be adjusted precisely to meet glycemic requirements.  
 when there is awareness of increased risk related to changes in dietary intake, physical 
activity, or inadvertent or atypi[INVESTIGATOR_362270]  
 to check for hyperglycemic events, or  
 as directed by [CONTACT_093].  
Performing a 6-point profile  
Participants will receive instructions to perform  SMBG 6 -point profiles over a 24 -hour period on 
2 nonconsecutive days during the 7 -day period prior to visits shown in the  SoA.  
The 6 -point profile consists of pre-meal and 2 -hour postprandial SMBG measurements for the 
morning , midday , and evening meals during 1 day.  
Pre-meal measurements should be taken before the participant begins eating the meal.  
When to measure fasting blood glucose (FBG) during the study  
Site personnel wi ll train the participant  to measure FBG daily when possible, and a minimum of 
3 times per week using the study -provided  glucometer.  
Participants should not eat or drink anything but water for a minimum of 8 hours before 
measuring their FBG.  
Participants sh ould measure FBG upon waking in the morning  after fasting overnight .   
Glucometer data transfer  
The study -provided glucometer will wirelessly transmit blood glucose measurements to the 
participant’s e -diary. Site personnel will be able to view SMBG data that have been transmitted 
to the e -diary through a web -based portal as well as any reported events of hypoglycemia.  
8.1.2.  Patient -Reported Outcomes   
To ensure balance between participa nts assigned to  LY3209590 or insulin glargine , all 
participants will complete the questionnaires .  
The self -administered questionnaires will be translated into the native language of the region and 
administered at the site during the designated visits in t he SoA.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
69 Order of administering the  questionnaires during the visit  
If the participant is not adversely affected by [CONTACT_51993], the questionnaires should be 
completed before the participant has discussed their medical condition or progress in t he study 
with the investigator or study personnel.  
Preferred administration order of these questionnaires is : 
1. TRIM -D  
2. DTSQ  
3. SIM-Q 
4. DID-EQ, and  
5. Basal Insulin Experience: Likelihood of incorporating into routine.   
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
70 [IP_ADDRESS].  Treatment -Related Impact Measure – Diabetes (TRIM -D)  
Description of TRIM -D 
The TRIM -D is a participant self -administered instrument, which assesses the impact of diabetes 
treatment on participants’ functioning and well -being across available diabetes treatments. 
Participants assess their experience “over the past 2 weeks.”  
The TRIM -D assesses [ADDRESS_744395].  
Domain  Number of items per domain  
Treatment Burden  6 
Daily Life  5 
Diabetes Management  5 
Compliance  4 
Psychological Health  8 
Scoring  
Each of the 28 items is assessed on a 5 -point scale, where higher scores indicate a better health 
state.  
[IP_ADDRESS].  Diabetes Treatment Satisfaction Questionnaire  – Status Version (DTSQ -s)  
Description of DTSQ -s 
The DTSQ -s (Bradley and Lewis 1990; Bradley 1999 ) is a diabetes -specific patient -reported 
outcome instrument that assesses the overall treatment satisfaction and perceived frequency of 
hyperglycemia and hypoglycemia. It is appropriate for use in both T1D and T2D. 
The DTSQ -s consists of [ADDRESS_744396] few weeks, prior to the visit.  
Scoring for DTSQ -s 
Each item is rated on a 7 -point Likert scale.  
Items 1, 4, 5 -7, and 8 are rated from 0 (very dissatisfied) t o 6 (very satisfied) and can be summed 
up to produce a treatment satisfaction score.   
Items 2 and 3 evaluate the perceived frequency of hyperglycemia and hypoglycemia and are 
rated from 0 (none of the time) to 6 (most of the time).   
[IP_ADDRESS].  Diabetes Treatment Satisfaction Questionnaire  – Change  Version (DTSQ -c)  
Description of DTSQ -c 
The DTSQ -c (Bradley 1999) was designed to overcome potential ceiling effects in the status 
version.   
The DTSQ -c has the same 8 items as the status version but is reworded slightly to measure the 
change in treatment satisfaction rather than absolute treatment satisfaction.  
Scoring for DTSQ -c 
Each item is scored on a scale of -3 to +3.   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
71 For items 2 and 3, representing perceived frequency of hyperglycemia, and perceived frequency 
of hypoglycemia , the lower the score  represent s better the perception.  
For the remaining  items  
 the higher the score  represent s the greater the improvement in treatment satisfaction  
 the lower the score  repres ents the greater the deterioration in treatment satisfaction, and  
 a score of 0 represents no change.  
[IP_ADDRESS].  Simplicity of Diabetes Treatment Questionnaire (SIM -Q) Single Medication 
Status Version   
Description of SIM -Q 
The SIM -Q is a brief [ADDRESS_744397] 2 questions of the SIM -Q will be completed  
 “How simple or complex is your medication treatment for diabetes?” and  
 “Overall, how simple or complex is it to manage your diabetes, including medication, 
checking your blood glucose levels, diet, and any other aspects of diabetes treatment?”  
Scoring  for SIM -Q 
Each item is scored on a 5 -point scale ranging fr om “Very complex” to “Very simple.”  
[IP_ADDRESS].  Diabetes Injection Device Experience Questionnaire ( DID-EQ) Version 1.0   
Description of DID -EQ 
The DID -EQ (Matza et al. 2018) is a self -administered, 10 -item questionnaire designed to assess 
participants’ perceptions of non -insulin diabetes injection delivery systems for T2D.  
Scoring for DID -EQ 
Each item is rated on a 4 -point scale with higher scores indicating more positive perceptions o f 
the injection device.  
Items 1 to 7 focus on specific characteristics of non -insulin injection device, and these 7 items 
comprise the Device Characteristics subscale.  
In addition, there are 3 global items :  
 Item 8 assessing overall satisfaction  
 Item 9 ease of use, and  
 Item 10 convenience of non -insulin injection devices.  
These 3 global items are each scored separately.  
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
72 [IP_ADDRESS].  Basal Insulin Experience: Likelihood of Incorporating into Routine   
Description of questionnaire  
The Basal Insulin Experience: Likelihood of incorporating into routine is a self -reported scale 
consisting of a single question to understand the participant’s likelihood of incorporating their 
study insulin into t heir diabetes management routine.  
Scoring  
The question is rated on a 5 -point scale with responses ranging from “very unlikely” to “very 
likely.”   
8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations   
The complete physical examination will include, at a minimum, assessments of these systems : 
 cardi ovascular  
 respi[INVESTIGATOR_696]  
 gastrointestinal, and  
 neurologic . 
Additional assessments include clinical signs and symptoms related to T2D, T2D -related 
illnesses, and injection -site reactions.  
Height and Weight  
Height and weight will be measured as outlin ed in the SoA. 
8.2.2.  Vital Signs   
Blood pressure and pulse rate will be measured as outlin ed in the SoA and as clinically indicated. 
Additional vital signs may be measured during study visits if warranted, as determined by [CONTACT_1275].  
8.2.3.  Electrocardiograms   
Local and single  12-lead ECG will be obtained as outlined in the SoA.  
ECG s will initially be interpreted by [CONTACT_566803], and ideally while the participant is still present, to 
determine whether the participant meets entry criteria and for  immediate participant 
management, should any clinically relevant findings be identified.  
The investigator or qualified designee is responsible for determining if any change in participant 
management is needed and must document their review of the ECG prin ted at the time of 
evaluation.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744398] be retained with source documents unless a Source Document 
Agreement or comparable document cites an electronic location that accommodates the expected 
retention duration.  
Clinically significant abnormal laboratory find ings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_41411] ’s condition.  
All laboratory tests with values considered clinically significantly abnormal during par ticipation 
in the study or within [ADDRESS_744399] bilirubin, GGT, and creatine kinase, 
should be repeated within 48 to 72 hours to confirm the abnormality and to determine if it is 
increas ing or decreasing, if 1 or more of these conditions occur. This table shows when to repeat 
laboratory tests.  
If a participant with baseline results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participants with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for participants with Gilbert’s 
syndrome)  
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744400] result persists or worsens, clinical and laboratory monitoring, and 
evaluation for possible causes of abnormal liver tests should be initiated by [CONTACT_566804] -designated medical monitor. At a minimum, this evaluation should 
include physical examination and a thorough medical history, including  
 symptoms  
 recent illnesses, for example, heart failure, systemic infection, hypotension, or seizures  
 recent tr avel 
 history of concomitant medications, including over -the-counter, herbal and dietary 
supplements, and  
 history of alcohol drinking and other substance abuse.  
Frequency of monitoring  
Initially, monitoring of symptoms and liver tests should be done 1 to 3 times weekly, based on 
the participant’s clinical condition and liver test results.  
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and laboratory results stabilize.  
Monitoring of  ALT, AST, ALP, and TBL should continue until levels normalize or return to 
approximate baseline levels.  
Comprehensive hepatic evaluation  
When to perform a comprehensive evaluation  
A comprehensive evaluation should be performed to search for possible cause s of liver injury if 
1 or more of the conditions in this table occur.  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs or symptomsa, or 
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participants with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs or symptomsa, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for participants with Gilbert’s syndrome)  
a Hepatic signs or symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, 
rash, and/or eosinophilia >5%.  
What a comprehensive evaluation should include  
At a minimum, this evaluation should include  
 physical examination and a thorough medical history, as outlined above  
 tests for  
o PT-INR 
o viral hepatitis A, B, C, or E, and  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
75 o autoimmune hepatitis, and  
 an abdominal imaging study, for example, ultrasound or comput ed tomography scan.  
Based on the patient ’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for  
 hepatitis D virus  
 cytomegalovirus  
 Epstein -Barr virus  
 acetaminophen l evels  
 acetaminophen protein adducts  
 urine toxicology screen  
 Wilson ’s disease  
 blood alcohol levels  
 urinary ethyl glucuronide, and  
 blood phosphatidylethanol.  
Based on the circumstances and the investigator ’s assessment of the participant ’s clinical 
condition , the investigator should consider referring the participant for a hepatologist or 
gastroenterologist consultation, magnetic resonance cholangiopancreatography, endoscopic 
retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
Addi tional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Collect additional hepatic safety data collection in the hepatic safety CRFs if a participant 
develops  
 a hepatic event considered to be  an SAE  
 discontinues study intervention due to a hepatic event, or  
 has changes in laboratory results described in this table.  
If a participant with 
baseline results of...  develops the following elevations…  Then…  
Elevated serum ALT  
Collect additional hepa tic safety data in 
the hepatic safety CRF.  ALT <1.5x ULN  ALT to ≥5x ULN on 2 or more 
consecutive blood tests  
ALT ≥1.5x ULN  ALT ≥3x baseline on 2 or more 
consecutive blood tests  
Elevated TBL  
TBL <1.5x ULN  TBL ≥2x ULN, except for participants 
with Gilbert’s syndrome  
TBL ≥1.5x ULN  TBL ≥2x baseline  
Elevated ALP  
ALP <1.5x ULN  ALP ≥2x ULN on 2 or more consecutive 
blood tests  
ALP ≥1.5x ULN  ALP to ≥2x baseline on 2 or more 
consecutive blood tests  
Note: The interval between the [ADDRESS_744401] 2 days.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744402] Complaints   
The definitions of the following events can be found in Section 10.3: 
 AEs 
 SAEs, and  
 PCs. 
These events will be reported by [CONTACT_442335], when appropriate, by a caregiver, surrogate, 
or the participant’s legally authorized representative.  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to the study intervention or study  procedures, or that caused the 
participant to discontinue the study intervention or study (see Section 7). 
Care will be taken not to introduce bias w hen detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent v isits or contacts. All SAEs  will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). 
For PCs, the investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality. Further information on 
follow -up procedures is provided in  Section 10.3. 
8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Adverse Event (AE)  
AE Signing of 
the informed 
consent form 
(ICF)  The last 
safety follow -
up visit  As soon as possible 
upon site awareness  AE CRF  N/A 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
77 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Serious Adverse Event (SAE)  
SAE and SAE 
updates  
prior to start of 
study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  Signing of 
the ICF  Start of 
intervention  Within [ADDRESS_744403] 
safety follow -
up visit  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
SAEa  
after study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  [ADDRESS_744404] dose  Within 24 hours  
(see Section 8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
Product Complaints (PC s) 
PC associated 
with an SAE or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
78 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed PC form 
with all changes 
signed and dated by 
[CONTACT_093]  N/A 
PC (if 
investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  PC form   
a SAE s should not be reported unless the investigator deems them to be possibly related to study 
treatment or study participation.  
8.3.2.  Pregnancy   
Collection of pregnancy information  
Male participants with partners who become pregnant  
The investigator will attempt to collect pregnancy information on any male participant’s female 
partner who becomes pregnant while the male participant is in this study. This applies only to 
male participants who receive LY3209590 or insulin glargine . 
After learning of a pregnancy in the female partner of a study participant, the investigator will 
obtain a consent to release information from the pregnant female partner directly, and within [ADDRESS_744405] pregnancy informat ion on the appropriate form and 
submit it to the sponsor.  
The female partner will also be followed to determine the outcome of the pregnancy. Information 
on the status of the mother and child will be forwarded to the sponsor. Generally, the follow -up 
will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the 
pregnancy will be reported regardless of gestational age, fetal status (presence or absence of 
anomalies), or indication for the procedure.  
Female participants who  become pregnant  
The investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. The initial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 h ours of learning of a participant ’s 
pregnancy.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744406] follow -up information on the participant and the neonate and the information will be 
forwarded to the s ponsor. Generally, follow -up will not be required for longer than 6 to 8 weeks 
beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of 
gestational age, fetal status (presence or absence of anomalies), or indication for the procedure.  
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
A spontaneous abortion (occurring at <20 weeks’ gestatio nal age) or still birth (occurring at ≥20 
weeks’ gestational age) is always considered to be an SAE and will be reported as such.  
Any poststudy pregnancy -related SAE considered reasonably related to the study intervention by 
[CONTACT_566805] 8.3.[ADDRESS_744407] 
discontinuat ion process and continue directly to the follow -up phase. The follow -up on the 
pregnancy outcome should continue independent of intervention or study discontinuation.  
8.3.3.  Cardiovascular Events   
A blinded external Clinical Event Committee will adjudicate potential cerebrocardiovascular 
events in a consistent and unbiased manner.  
Events include  
 death  
 myocardial infarction  
 coronary revascularization procedure  
 hospi[INVESTIGATOR_10929]  
 hospi[INVESTIGATOR_19934], and  
 stroke or transient ischemic attack.  
8.3.4.  Systemic Hypersensitivity Reactions   
Many drugs, including biologic agents, carry the risk of systemic hypersensitivity reactions. If 
such a reaction occurs, additional data should be provided to the sponsor in the designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participa nts are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of a suspected systemic hypersensitivity event, additional blood  samples should be 
collected as described in Section 10.2.1 . Laboratory results are provided to the sponsor via the 
central laboratory.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
80 8.3.5.  Injection -Site Reactions   
Symptoms and signs of a local injection -site reaction may include erythema, induration, pain, 
pruritus, lipodystrophy, and edema.  
If an injection -site reaction is reported by a participant or study personnel, additional information 
about this reaction will be collected in the CRF.  
8.3.6.  Hypoglycemia   
Participants will be trained by [CONTACT_566806]. Hypoglycemia events entered into the participant e -
diary will be available for review through a web -based portal that can be accessed by [CONTACT_566807].  
Hypoglycemia classification and definitions  
Level 1  
Glucose ≥54 mg/dL (3.0  mmol/L) to <70 mg/dL (3.9  mmol/L)  
Level [ADDRESS_744408] -acting 
carbohydrates. Providers should conti nue to counsel participants to treat hypoglycemia at this 
glucose alert value.  
Level 2  
Glucose <54  mg/dL (3.0  mmol/L)  
Level [ADDRESS_744409] required assistance and is not predicated on the report 
of a participant simply having received assistance.  
Examples of severe hypoglycemia in adults are  
 altered  mental  status  and the inability to assist in their own care  
 semiconscious or unconscious, or  
 coma  with or without  seizures . 
Glucose  measurements  may not be available during  such an event, but neurological recovery  
attributable to the restoration of  glucose concentration  to normal  is considered  sufficient  
evidence that the event was induced by  a low glucose concentration.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744410] the event as 
serious on the AE CRF and report it to Lilly as an SAE.  
The investigator should also determine if repeated or prolonged epi[INVESTIGATOR_291579].  
8.4. Pharmacokinetics   
At the visits and times specified in the SoA, blood  samples will be collected for all participants , 
regardless of whether participants transition to prefilled pen  during the study . Only samples from 
participants assigned to treatment with LY3209590  will be analyzed for drug concentration.  
Instructions for the collection and handling of blood samples will be provided by [CONTACT_456] . 
The actual date and time (24 -hour clock time) of each sampling wi ll be recorded.  
Bioanalytical  
Samples will be analyzed at a laboratory designated by [CONTACT_17077] a facility 
designated by [CONTACT_456]. Concentrations of LY3209590 will be assayed using a validated 
bioanalytical method.  
Sample retention is des cribed in Section  10.1.12 .  
8.5. Pharmacodynamics   
Pharmacodynamic parameters are described as part of the efficacy assessments in Section 8.1. 
8.6. Genetics   
Genetics are not evaluated in this study.  
8.7. Biomarkers   
Serum and plasma samples will be used for exploratory biomarker research, where local 
regulations allow. See Clinical Laboratory Tests in Section 10.2, and the SoA for sample 
collection information.  
Samples will be used for research on the drug target, disease process, variable response to 
LY3209590  pathways associated with T 2D, mechanisms of action of LY3209590 or research 
methods, or in validating diagnostic tools or assay(s) related to T2D.  
Samples may be used for research to develop methods, assays, prognostics, and/or companion 
diagnostics related to the intervention targ et, disease state, pathways associated with disease, 
and/or the mechanism of action of the study intervention . 
Sample retention is described in  Section 10.1.12 .  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744411] LY 3209590 . Antibodies may be 
further characterized for cross -reactive binding to endogenous insulin.  
To interpret the results of immunogenicity, a corresponding venous blood sample will b e 
collected at the same visits to determine the concentrations of LY3209590 (PK sample) . At 
Visit  3, the sample for immunogenicity should be taken before dosing and the PK sample for 
LY3209590 after dosing.  
Instructions for the collection and handling of b lood samples will be provided by [CONTACT_456].  
TE ADA is defined in Section [IP_ADDRESS] . 
Immunogenicity will be assessed by a validated assay designed to detect and characterize ADA in the 
presence of LY3209590 at a laboratory approved by [CONTACT_456].  
Sample retention is describe d in Section 10.1.12 . 
8.9. Health Economic s  
Health economics parameters are not evaluated in this study . 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744412] the hypothesis that LY3209590 is not inferior to 
insulin glargine  on glycemic control as measured by [CONTACT_51971]1c from b aseline to Week 52 
(Visit 3 3) in participants with T2D who are starting basal insulin for the first time.  
The null hypothesis ( H0) is the difference between LY3209590 versus insulin glargine  in the 
change from baseline to Week 52  (Visit 3 3) in HbA1c is greater than the NIM.  
The NIMs of 0.4% and 0.3% will both be tested to meet regulatory requirements. The 2 -sided 
95% CI will be used for testing the noninferiority.  
Secondary Hypothes is 
The key secondary (gated) objective is to test the hypothes is that LY3209590 is  superior to 
insulin glargine  for change from baseline to Week 52 (Visit 3 3) in HbA1c . 
H0: the difference (LY3209590 -insulin glargine ) ≥0.0 . 
A gatekeep er approach  (Westfall and Krishen 2001) will be used to control for type I error for 
the primary and gated secondary objective.  
9.2. Analyses  Sets  
This table defines the populations for the purpose of analysis.  
Analysis Populations or Datasets  Description  
Entered Population  All participants who sign the  informed consent form . 
Randomized  Population  All randomized participants . Participants will be analyzed according  to 
the treatment they were assigned . 
Modified Intent -to-Treat (mITT) 
Population  All randomized  participants who took at least 1 dose of study treatment.  
Participants will be analyzed according to the treatment they were 
assigned.  
Efficacy Analysis Set 1 (EAS1) for 
treatment regimen estimand  The data will include  
 mITT Population excluding participants discontinuing the 
study treatment due to inadvertent enrollment , and  
 all measurement s regardless of the use of study treatment or 
rescue medications .  
Efficacy Analysis Set 2 (EAS2) for 
efficacy estimand  The data will include  
 mITT Population excluding participants discontinuing the 
study treatment due to inadvertent enrollment , and  
 measurement s up to the discontinuation of study treatment or 
the initiation of rescue medication.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
84 Safety Analysis Set (SS)  The data will include  
 mITT Population , and 
 all measurement s regardless of the use of study treatment or 
rescue medications . 
 
9.3. Statistical Analyses   
9.3.1.  General Considerations   
Statistical analysis of this study will be the responsibility of Lilly or its designees.  
Any change to the data analysis methods described in the protocol will require an amend ment 
ONLY if it changes a principal feature of the protocol. Any other changes to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the SAP or the final clinical study report. Additional exploratory analyses of data will be 
conducted as deemed appropriate.  
Unless otherwise stated, the efficacy analyses will be conducted on either EAS1 or EAS2 , and 
the safety analyses will be conducted on the SS. A ll tests of treatment effects will be condu cted 
at a 2 -sided alpha level of 0.05 and 2 -sided 95% CIs will be calculated.  
Unless otherwise stated, the other secondary and tertiary  efficacy measures will be analyzed 
using the data up to the discontinuation of study treatment  (EAS2) , defined by [CONTACT_566808] +10 days or the initiation of rescue medication, whichever is earlier.  
Handling of missing, unused, and spurious data are addressed prospectively in the overall 
statistical methods described in the protocol and in the SAP, where appro priate. Adjustments to 
the planned analyses are described in the final clinical study report . 
 
9.3.2.  Primary Endpoint  or Estimand  Analysis   
The primary objective is to compare the HbA1c change from baseline to Week 52 (Visit 3 3) 
between LY3209590 and insulin glargine  and will be based on either of these 2 estimands : 
treatment regimen estimand for registration in the [LOCATION_002] , and 
efficacy estimand for registration in other countries.  
The 2 -sided 95% CI of the LS mean for individual treatment groups  and treatment LS mean 
difference for the HbA1c change from baseline to Week 52  (Visit 3 3) will be estimated.  
For both estimands, LY3209 590 will be declared noninferior to insulin glargine  if the upper limit 
of the 2 -sided 95% CI for the LS mean difference in the HbA1c change from baseline is below 
NIM (+0.4% or +0.3% for different regulatory requirements).  
The HbA1c is reported in unit of  % and will be converted to the unit of mmol/mol using th is 
formula : 
HbA1c in mmol/mol = 10.93 * HbA1c in % - 23.5 ( NGSP, 2010 ). 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
85 Treatment regimen estimand  
The treatment regimen estimand will be based on  the HbA1c data at baseline and Week 52  (Visit 
33) for the EAS1 , regardless of the use of study intervention or rescue medications.  
Missing measures  
Missing measures at the primary endpoint will be imputed using multiple imputation by [CONTACT_566809]. The retrieved dropout participants are t hose who discontinue study 
intervention prior to Week 52 (Visit 33 ) but have non -missing measures at Week 52  (Visit 33 ). 
If there are only a limited number of retrieved participants that leads to a failure in performing 
the multiple imputation analysis, su ch as the model cannot converge, or the number of retrieved 
dropout participants is small, the missing HbA1c at Week 52  (Visit 33 ) will be imputed by 
[CONTACT_51999] -to-baseline multiple imputations.  
Analysis model  
After the imputation, the observed and imputed dat a will be analyzed by [CONTACT_52000].  The 
model will include treatment  (LY3209590 and insulin glargine) , strata (country, GLP -1 RA 
treatment at randomization), and baseline value of the dependent variable. The statistical 
inference will be based on the multiple imputation framework by [CONTACT_11369] (1987).  
Efficacy estimand  
The efficacy estimand is the treatment dif ference in the change of HbA1c from baseline to Week 
52 (Visit 3 3) if all participants adhere to the treatment without intercurrent events.  
The HbA1c collected at all planned postbaseline visits  from the EAS2  will be used in the 
analysis . 
Missing measures  
There may be missing values due to the early discontinuation of study treatment or use of rescue 
medication.  
Analysis model  
The MMRM model will be used, and the missing values will be handled  in the MMRM analysis 
under the assumption of missing at random. The MMRM model will include treatment 
(LY3209590 and insulin glargine) , strata (country, GLP -1 RA treatment at randomization ), visit 
and treatment -by-visit interaction as fixed effects, and baseline of the dependent variable as a 
covariate. The Kenward -Roger approximation will be used to estimate denominator degrees of 
freedom for the MMRM models.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
86 An unstructured covariance structure will be used to model the within -participant errors. If this 
structure fails to converge, the following covarian ce structures will be used in order until one 
converges:  
1. Toeplitz with heterogeneity  
2. autoregressive with heterogeneity  
3. compound symmetry with heterogeneous variances  
4. Toeplitz  
5. autoregressive  
6. compound symmetry without heterogeneous variances.  
Change in LY3209590 administration device, from autoinjector to prefilled pen , will not be 
considered as an intercurrent event. Thus, the  2 estimands described above will include all 
participa nts who received LY3209590 study treatment irrespective of the a dministration device.  
9.3.3.  Secondary Endpoint (s) Analysis   
[IP_ADDRESS].  Gated  Endpoints   
The superiority test in change from baseline to Week 52  (Visit 3 3) in HbA1c will be conducted if 
LY3209590 was declared noninferior to insulin glargine  for the primary endpoint analysis .  
Superior ity test 
The superiority test in change from baseline to Wee k 52 (Visit 3 3) in HbA1c will be based on the 
same primary endpoint analysis described above.  
[IP_ADDRESS].  Other Secondary Endpoints   
Other secondary endpoints include various measures for ef ficacy, safety, and patient -reported 
outcome questionnaires.  
Unless otherwise stated, efficacy measures and patient -reported questionnaires will be analyzed 
using the EAS2 . 
Safety measures will be analyzed using the SS regardless of treatment discontinuati on and use of 
rescue medications.  
Analysis details will be provided in the SAP.   
9.3.4.  Tertiary  Endpoint (s) Analysis   
Analy ses for tertiary endpoints  will be  provided in the SAP . 
9.3.5.  Safety  Analyse s  
Safety measures include  
 treatment exposure  
 AE 
 vital signs  
 weight  
 hypoglycemia  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
87  laboratory measures , and 
 immunogenicity.  
All safety analyses will be based on the SS. 
Events that are newly reported after the first dose of LY3209590 or insulin glargine , or reported 
to worsen in severity from baseline, will be considered TEAEs. The Medical Dictionary for 
Regulatory Activities (MedDRA) lowest level term will be used in the  treatment -emergent 
assessment. The maximum severity for each lowest level term during the baseline period will be 
used as baseline severity.  
Summary statistics will be provided for incidence of  
 TEAEs  
 SAEs  
 study discontinuation due to AEs  
 intervention disc ontinuation due to AEs, and  
 deaths.  
Hypoglycemia analysis  
The analysis periods of 0 -16, 0-26, 0 -52, 1 6-26, and 26 -52 weeks of treatment will be 
considered.  
The participant -reported hypoglycemia will be analyzed using data from the e -diary by  
 Level 1 (gluc ose ≥54 to <70  mg/dL)  
 Level 2 (glucose <54  mg/dL)  
 Level 3 (severe), and  
 the composite of Levels 2 and 3.  
This table gives definitions for documented hypoglycemia events.  
Documented hypoglycemia  Definition  
All documented hypoglycemia  epi[INVESTIGATOR_51952] 24-hour period  
Non-nocturnal hypoglycemia   epi[INVESTIGATOR_51953] 0600 hours  to midnight  
Nocturnal hypoglycemia   epi[INVESTIGATOR_51954] 0600 hours   
The incidence and rate of hypoglycemia will be summarized by [CONTACT_517509].  
For continuous safety variables, such as laboratory measures, vital signs and weight, MMRM or 
ANCOVA models will be used.  
For categorical safety variables, such as AEs, incidence of hypoglycemia, and treatment -
emergent abnormal labo ratory measurements, either Fisher’s exact test or logistic regression will 
be used for treatment comparison.  
Further details for assessing all safety measures will be provided in the SAP.   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
88 9.3.6.  Other Analyses   
[IP_ADDRESS].  Pharmacokinetic and Pharmacodynamic Analyses   
LY3209590 concentration data will be analyzed using a population PK approach via nonlinear 
mixed -effects m odeling with the NONMEM software.  
The relationships between LY3209590 dose , concentration , formulation s and device, efficacy, 
safety and biomarker endpoints may be characterized.  
The impact of additional participant factors, such as age, weight, gender, and renal function on 
PK and/or PD parameters may be examined , if deemed necessary .  
If ADA  is detected from immunogenicity testing, its impact on LY3209590 PK or any relevant 
PD param eters will be examined.  
[IP_ADDRESS].  Evaluation of Immunogenicity   
The baseline ADA  status , as detected or not detected , against LY3209590 , will be summarized 
by [CONTACT_566810] , defined as participants with non -missing 
baseline and at least 1 non-missing postbaseline measurement.  
Definition of TE  ADA  
A participant is considered TE ADA  positive (TE ADA +) if either treatment -induced ADA or 
treatment -boosted ADA occur.  
Treatment -induced ADA  is defined as the participant having a baseline status of ADA Not 
Present and at least 1 postbaseline status of ADA Present with titer ≥2 -fold (1 dilution) of the 
minimu m required dilution (1:20) . 
Treatment -boosted ADA  is defined as the participant having a baseline status of ADA Present 
and at least 1 postbaseline status of ADA Present with the titer being ≥ 4-fold ( 2 dilutions) of the 
baseline titer.  
Immunogenicity  analyses 
The baseline LY3209590 ADA status, as detected or not detected, will be summarized by 
[CONTACT_566811].  
The number and percentage of  participants who are TE  ADA  positive (TE  ADA+) will be 
summarized by [CONTACT_1570].  
The frequency of cross -reactive binding to endogenous insulin s may be summarized for the 
participants who are TE  ADA+.  
The relationship between the presence of TE  ADA and the safety and efficacy measures may be 
assessed.  
9.3.7.  Sensitivity Analyses   
Sensitivity analyses will be conducted excluding the data after  the change  to LY3209590 
titratable dosing with a prefilled pen  to compare the HbA1c change from baseline to Week 52 
(Visit 33) between LY3209590 with the fixed dose regimen and insulin glargine.    
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
89 Analys es details will be provided in the SAP.  
9.4. Interim Analys is  
A program level -safety review usin g selected efficacy and safety data will be conducted on a 
periodic basis across all ongoing Phase 3 clinical trials evaluating LY3209590. The analysis will 
be performed using the unblinded data and be reviewed by [CONTACT_52007] (Section 10.1.5 ). 
Study team personnel will remain blinded. Detailed information for the data review and the 
unblinding are specified in the DMC charter or a separate unblinding plan document.  
9.5. Sample Size Det ermination   
Approximately 670 participants will be randomly assigned to LY3209590 and insulin glargine  in 
a 1:1 ratio.  
With the assumption of 15% dropout at Week 52  (Visit 33) , approximately [ADDRESS_744413] 99% statistical power to show noninferiority 
between LY3209590 and insulin glargine  using the upper limit of a 2 -sided 95% CI and these 
assumptions  
 NIM of 0.4%  
 no true difference between treatment groups, and  
 an SD of 1.1% . 
This sample size has at least 90% statistical power to show noninferiority between LY3209590 
and insulin glargine  using a 0.3% NIM at Week 52  (Visit 33) . 
The number of  completers will provide 90% statistical power to show  superiority between 
LY3209590 and insulin glargine  for change in HbA1c from baseline to Week 52 (Visit 33) , 
assuming an SD of 1.1% and true mean diff erence of -0.3%, and alpha of 0.05.  
 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
90 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
This study will be conducted in accordance with the protocol and with the following : 
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines  
o Applicable ICH GCP Gui delines  
o International Organization for Standardization (ISO) [ZIP_CODE] , and  
o Applicable laws and regulations.  
The protocol, protocol amendments, ICF, IB, and other relevant documents ( for example , 
advertisements) must be submitted to an IRB/IEC by [CONTACT_566812]/IEC  before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study 
participants . 
The investigator will be resp onsible for the following : 
○ Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
○ Notifying the IRB/IEC of SAEs or other  significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 Code of Federal Regulations, ICH 
guidelines, the IRB/IEC, European regulat ion 536/2014 for clinical studies, if 
applicable, and all other applicable local regulations, and  
o Reporting significant issues related to participant safety, participant rights, or data 
integrity.  
Investigator sites are compensated for participation in the  study as detailed in the clinical trial 
agreement.  
10.1.2.  Financial Disclosure   
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
91 certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process   
The investigator or the investigator’s representative will explain the nature of th e study, 
including the risks and benefits, to the participant and answer all questions regarding the study.  
Participants must be informed that their participation is voluntary. Participants will be required to 
sign a statement of informed consent that meet s the requirements of 21 Code of Federal 
Regulations 50, local regulations, ICH guidelines, privacy and data protection requirements, 
where applicable, and the IRB/IEC or study center.  
The medical record must include a statement that written informed conse nt was obtained before 
the participant was entered in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study.  
A copy of the ICF(s) must be provided to the participant and is kept on file.  
10.1.4.  Data Protection   
Participants will be assigned a uniq ue identifier by [CONTACT_456]. Any participant records, datasets, 
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be transfer red. 
The participant must be informed that the participant’s personal study -related data will be used 
by [CONTACT_10999]. The level of disclosure must also be 
explained to the participant who will be required to giv e consent for their data to be used as 
described in the informed consent.  
The participant must be informed that their medical records may be examined by [CONTACT_11000], by 
[CONTACT_17081]/IEC members, and by [CONTACT_6668].  
The sponsor has processes in place to ensure data protection, information security, and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data security breach.  
10.1.5.  Committees Structure   
[IP_ADDRESS].  Internal Safety Review Team   
Participant safety will be continuously monitored by [CONTACT_456]’s internal safety review team, 
which includes safety signal detection at any time during the study.  
All safety data collected will be summarized and reviewed by [CONTACT_456]’s internal safety 
review team for agreement of next steps.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
92 [IP_ADDRESS].  Clinical Event Committee for Adjudication of Events   
A blinded Clinical Event Committee, external to Lilly, will adjudicate all deaths and 
cerebrocardiovascular events. The committee will include physicians external to Lilly with 
cardiology expertise.  
[IP_ADDRESS].  Data Monitoring Committee   
An independent, external DMC will be responsible for reviewing unblinded data during the 
study.  
The committee will include, at a minimum, a medical physician with appropriate expertise and a 
statistician.  
Access to the unblinded data will be limited to the DMC and the external Statistical Ana lysis 
Center statisticians who are providing the analysis of the data. These statisticians will be 
independent from the study team. The study team will not have access to the unblinded data. 
Only the DMC is authorized to evaluate unblinded interim analyses . 
Details about the membership, purpose, responsibilities, and operation will be included in the 
DMC charter.  
10.1.6.  Dissemination of Clinical Study Data   
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by [CONTACT_51967].  
The summary of results will be posted within the time frame specified by [CONTACT_51967]. 
If the stu dy remains ongoing in some countries and a statistical analysis of an incomplete dataset 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overall analyses (for example, trial not yet unblinded ), the summary of results 
will be submitted within [ADDRESS_744414], see the instructions provided at www.vivli.org.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744415] maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
Data monitoring and management  
Quality tolerance limits will be predefined to identify systematic issues that can impact 
participant safety and/or reliability of study results. These predefined parameters will be 
monitored during the study and important excursions from the quality tolerance limits and 
remedial actio ns taken will be summarized in the clinical study report . 
Monitoring details describing strategy (for example, risk -based initiatives in operations and 
quality such as risk management and mitigation strategies and analytical risk -based monitoring), 
methods , responsibilities and requirements, including handling of noncompliance issues and 
monitoring techniques are provided in the Monitoring Plan.  
The sponsor or designee is responsible for the data management of this study, including quality 
checking of the d ata. 
The sponsor assumes accountability for actions delegated to other individuals, for example, 
contract research organizations.  
Study monitors will perform ongoing source data verification to confirm that data transcribed 
into the CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements,  ICH GCP, and all applicable regulatory requirements.  
Records retention and audits  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_566813] a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party  without written notification to the sponsor.  
In addition, sponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study site. The study may be audited by [CONTACT_566814], and/or regulatory agencies at any time. Investigators will be given notice before 
an audit occurs.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744416] data captured in the EDC system and will serve as the source documentation . 
Additionally, electronic clinical outcome assessment data (participant -focused outcome 
instrument) will be directly recorded by [CONTACT_566815] , into an instrument, for 
example, hand -held smart pho ne or tablet . The electronic clinical outcome assessment  data will 
serve as the source documentation, and the investigator does not maintain a separate written or 
electronic record of these data.  
Data storage and access  
Data collected via the sponsor -provi ded data capture system s will be  stored at third parties . 
The investigator will have continuous access to the data during the study and until 
decommissioning of the data capture system s. Prior to decommissioning, the investigator will 
receive or access an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system, and reports  will be provided to the investigator for review 
and retention.  Data will subsequently be transferred from the central vendor to the sponsor data 
warehouse.  
Data from complaint forms submitted to the sponsor will be encoded and stored in the global PC 
management system.  
10.1.8.  Source Documents   
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s sit e. 
Data reported on or entered in the CRF and are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator 
may need to request previous medical records or transfer records, depe nding on the study. Also, 
current medical records must be available.  
Definition of what constitutes source data can be found in 10.1.7 . 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744417] of recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
Study or site termination  
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when a ll required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of th e intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]  
 study termination  
o discontinuation of further study intervention development  
 site termination  
o failure of the investigator  to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor’s procedures, or GCP guidelines  
o inadequate recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_093], or  
o total number  of participants included earlier than expected.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the stud y of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
10.1.10.  Publication Policy   
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.11.  Investigator Information   
Researchers with appropriate education, training, and experience, as determined by [CONTACT_456], 
will participate as investigators in this clinical trial.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
96 10.1.12.  Sample Retention   
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development of 
LY3209590 or after LY32095 90 become(s) commercially available.  
Sample Type  Custodian  Maximum Retention Period after Last Patient Visita 
Exploratory biomarkers   Sponsor or designee  15 years  
Pharmacokinetic  Sponsor or designee  1 year  
Immunogenicity   Sponsor or designee  15 years  
a Sample retention period s may differ dependent upon local regulations.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
97 10.2. Appendix 2: Clinical Laboratory Tests   
The clinical laboratory tests will be performed by [CONTACT_11008] -design ated laboratory or by [CONTACT_566816] . 
Local laboratory results are only required in the event that the central laboratory results are not 
available in time for either study intervention administration and/or response evaluation. If a 
local sample is required, it is important that the sample for central analysis is obtained at the 
same time. Additionally, if the local laboratory results are used to make either a study 
intervention decision or response evaluation, the re sults must be recorded.  
In circumstances where the sponsor approves local laboratory testing in lieu of central laboratory 
testing (in the table below), the local laboratory must be qualified in accordance with applicable 
local regulations.  
Protocol -specif ic requirements for inclusion or exclusion of participants are detailed in Section [ADDRESS_744418] document their review of the laboratory safety results.  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
98  
Clinical Laboratory Tests   Comments  
Hematology  Assayed by [CONTACT_11007] -designated labora tory 
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs - red blood cells)    
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Leukocytes (WBCs - white blood cells)    
Differential    
Percent and absolute count of:   
  Neutrophils, segmented    
  Lymphocytes    
  Monocytes    
  Eosinophils    
  Basophils    
Platelets    
Clinical Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Sodium    
Potassium    
Chloride    
Bicarbonate    
Total bilirubin    
Direct bilirubin    
Alkaline phosphatase (ALP)    
Alanine aminotransferase (ALT)    
Aspartate aminotransferase (AST)    
Gamma -glutamyl transferase (GGT)    
Blood urea nitrogen (BUN)    
Creatinine    
Uric acid    
Total protein    
Albumin    
Calcium    
Phosphorus    
Glucose  Fasting or random (Refer to SoA)  
Cholesterol    
Triglycerides    
Lipid Panel  Assayed by [CONTACT_11007] -designated laboratory  
High -density lipoprotein (HDL)    
Low-density lipoprotein (LDL -C) This value will be calculated. If triglycerides >400  mg/dL, 
the direct LDL will be assayed  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
99 Very -low-density lipoprotein (VLDL -C)   
Urinalysis  Assayed by [CONTACT_11007] -designated laboratory  
Specific gravity    
pH   
Protein    
Glucose    
Ketones    
Bilirubin    
Urobilinogen    
Blood    
Nitrite    
Urine leukocyte esterase    
Microscopic examination of sediment    
Hormones (female)    
Serum pregnancy  Assayed by [CONTACT_11007] -designated laboratory  
Urine pregnancy  Evaluated locally  
Follicle -stimulating hormone (FSH)  Assayed by [CONTACT_11007] -designated laboratory. Performed as 
needed to confirm participant’s postmenopausal status  
Urine Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Albumin   
Creatinine   
Calculations  Generated by [CONTACT_11007] -designated laboratory  
eGFR (CKD -EPI)    
Urinary albumin/creatinine ratio (UACR)    
Pharmacokinetic Samples  
LY3209590 concentration  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
Additional Testing  Assayed by [CONTACT_11007] -designated laboratory  
C-Peptide    
HbA1c    
Glucose  Fasting per SoA  
Exploratory Biomarker Storage Samples  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
Serum    
Plasma (EDTA)    
Immunogenicity Samples  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
Anti-LY3209590 antibodies    
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744419] from 30 min to 4 hr after 
the start of the event.  
Note: The optimal collection time 
is from 1 to 2 hr after the start of 
event.  Serum  Total trypta se 
Serum  Complements ( C3, C3a, and C5a)  
Serum  Cytokine panel ( IL-6, IL‐1β, IL‐10, or any cytokine 
panel that includes these 3 cytokines)  
Collect samples on the same day as 
the event.  
If samples were already collected 
per the SoA on the same day as the 
event, then duplicate samples are 
not collected.  
Note: The optimal collection time 
is up to 12 hr after the start of the 
event.  Serum  LY3209590 ADAs  
Plasma  LY3209590 concentration  
Abbreviations: ADA s = antidrug antibodies; IL = interleukin.  
a All samples for hypersensitivity testing will be assayed by [CONTACT_11007] -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protoco l deviation.  
Information to record  
Record the date and time when the samples are collected.  
Allowed additional testing for participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant ma nagement.  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
101 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and Reporting   
 The definitions and procedures detailed in this appendix are in accordance with ISO 
[ZIP_CODE].  
 Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.[ADDRESS_744420] of 
study-related  medical devices.  
10.3.1.  Definition of AE   
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical pr oduct and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable  and unintended sign 
(including an abnormal laboratory finding), symptom, or disease  (new or exacerbated)  
temporally associat ed with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
 An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory f inding) in study participants, users, or 
other persons, whether or not related to the investigational medical device. This 
definition includes events related to the investigational medical device or comparator 
and events related to the procedures involved except for events in users or other 
persons, which only include events related to investigational devices.   
 
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments  (for ex ample , ECG, radiological scans,  and vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is , not related 
to progression of underlying disease).  
 Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of IMP, including signs, symptoms, or clinical 
sequelae. See definitions in Section  10.8. 
 Lack of efficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the effi cacy assessments. 
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
102 However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfil l the definition of an AE or SAE.   
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease/dis order being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
 Medical or surgical procedure ( for example , endoscopy  and appendectomy): the 
condition that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected a t the start of the study that do not worsen.  
10.3.2.  Definition of SAE   
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_10909]  
 In general, hospi[INVESTIGATOR_51955] (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physicia n’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be 
considered serious.  
 Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
103 d. Results in persistent disability/incapacity  
 The term disability means a substantia l disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental traum a (for example , sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies,  and ectopic pregnancy) are considered SAEs.  
f. Other situations  
 Medical or scientific judgment should be exercised by [CONTACT_566817] -threatening or result in death or hospi[INVESTIGATOR_51957]. These ev ents should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse.   
g. Result s in medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.   
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744421] Complaint  
 A PC is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness or performance of a 
study intervention . When the ability to use the study intervention safely is i mpacted, 
the following are also PCs: 
o Deficiencies in labeling information, and  
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product.  
 PCs related to study inte rventions used in clinical trials are collect ed in order to ensure 
the safety of participants, monitor quality, and to facilitate process and product 
improvements.  
 Investigators will instruct participants to contact [CONTACT_11010] a PC or problem with the study inte rvention so that the situation can be assessed.  
 An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and Product Complaint  Recording  
 When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /PC information in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice. AE/SAE info rmation is reported on the appropriate CRF page and PC 
information is reported on the Product Complaint Form . 
Note: An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the Product Complaint Form for PCs. 
 There may be instances when copi[INVESTIGATOR_517482] . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_566783] . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.   
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
105 Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:   
 Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living.  
 Moderate:  A type of AE that is usually alleviated with additional specific therapeu tic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of AE that interrupts usual activities of daily living, or signi ficantly 
affects clinical status, or may require intensive therapeutic intervention . An AE that is 
assessed as severe should not be confused with a n SAE. Severe is a category utilized 
for rating the intensity of an event; and both AEs and SAEs can be asses sed as severe.  
An event is defined as “serious ” when it meets at least one of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.   
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  The investigator will use clinical judgment to 
determine the relationship . 
 A “reasonable possibility ” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administr ation will be considered and investigated.  
 The investigator will also consult the IB  for LY3209590  and the Product Information 
for insulin glargine  in their assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to sponsor or designee . However, it 
is very important that the  investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to sponsor or designee . 
 The investigator may change their opi[INVESTIGATOR_9242] -up 
information and send a n SAE follow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
106  
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_11011]/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period,  the inv estigator will provide sponsor or designee  with a copy of any 
postmortem findi ngs including histopathology.  
10.3.5.  Reporting of SAEs   
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see 
next section) in order to report the event within 24 hours.   
 The site will  enter the SAE data into the electronic system as soon as it becomes 
available.  
 After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site  receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a n SAE paper form (see next 
section) or to the sponsor by [CONTACT_756].  
 Contacts for SAE reporting can be found in site training documents .  
 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the sponsor . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in site training documents . 
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
107 10.3.6.  Regulatory Reporting Requirements   
SAE Regulatory Reporting  
 Prompt notification by [CONTACT_11012] a n SAE is essential so 
that legal obligations and ethical responsibilit ies towards the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRBs/IEC s, and investigators.  
● An investigator who receives an investigator safety report describing a n SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the s ponsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.    
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
108 10.4. Appendix 4: Contraceptive and Barrier Guidance   
10.4.1.  Definitions   
Word/Phrase  Definition  
Women of childbearing 
potential (WOCBP)  Adult females are considered WOCBP unless they are WNOCBP . 
Women not of 
childbearing potential 
(WNOCBP)  Females are considered WNOCBP  if they  
 have a congenital anomaly such as Müllerian agenesis  
 are infertile due to surgical sterilization, or  
 are postmenopausal.  
Examples of surgical sterilization include total hysterectomy, bilateral salpi[INVESTIGATOR_8936] -
ooph orectomy, bilateral salpi[INVESTIGATOR_1656], or bilateral oophorectomy.  
Postmenopausal state  The postmenopausal state is defined as a woman:  
 at any age at least [ADDRESS_744422] -surgical bilateral oophorectomy with or 
without hysterectomy, confirmed by [CONTACT_31083]; or  
 aged at least [ADDRESS_744423] 12 
consecutive months without an alternative medical cause, AND with a 
follicle -stimulating hormone >40 mIU/mL; or  
 [ADDRESS_744424] 12 months of 
spontaneous amenorrhea, or  
 aged at least 55 years with a diagnosis of menopause prior to starting 
hormone replacement therapy.  
 
a Women should not be taking medications during ameno rrhea such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, SERMs, 
or chemotherapy that could induce transient amenorrhea.  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
109 10.4.2.  Contraception Guidance   
Guidance for women of childbearing potential  
This outlines the rules for WOCBP to ensure they do not become pregnant during the study.  
If, as part of their preferred and usual lifestyle, 
WOCBP…  Then…  
are in a same -sex relationship  they must stay in same -sex relationships without sexual 
relationships with males . 
are completely abstinent  they must agree to remain completely abstinent  
are not completely abstinent  they must agree to  
 use 1 highly effective method  of 
contraception, or a combination  of 2 effective 
methods of contraception, and  
 pregnancy test ing.  
Participants must have a negative serum pregnancy test 
at screening followed by a negative urine result within 
[ADDRESS_744425] do se of intervention . See the SoA 
for testing requirements.  
Note on forms of contraception:  The methods  of contraception must be used for the duration of  the study .  
 
Guidance for all men  
No male contraception is required except in compliance with specific local government study 
requirements.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
110 Methods of contraception for women of childbearing potential  
Methods  Examples  
Highly effective contraception (less than 1% failure 
rate)  female sterilization  
 combination oral contraceptive pi[INVESTIGATOR_4382]  
 progestin -only contraceptive pi[INVESTIGATOR_4382] (mini -pi[INVESTIGATOR_4382]) 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 pounds or 
90 kg) 
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913])  
 combined contraceptive vaginal ring, or   
 intrauterine devices . 
Effective contraception   cervical sponges  
 barrier method with use of a spermicide  
o male or female condom with spermicide , 
or 
o diaphragm with spermicide  
Note: The barrier method must include use of a 
spermicide to be considered effective.  
Ineffective forms o f contraception  whether used alone 
or in any combination   spermicide alone  
 periodic abstinence  
 fertility awareness (calendar method, temperature 
method, cervical mucus, or symptothermal)  
 withdrawal  
 postcoital douche, or  
 lactational amenorrhea.  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
111 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments   
Hepatic Evaluation Testing  
See Section  8.2.[ADDRESS_744426] bilirubin  
Erythrocytes (RBCs - red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs - white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
    Neutrophils, segmented  Gamma -glutamyl transferase (GGT)  
    Lymphocytes  Creatine kinase (CK)  
    Monocytes  Other Chemistry  
    Basophils  Acetaminophen  
    Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
Ethyl alcohol (EtOH)  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin IgA (quantitative)  
 
Hepatitis A virus (HAV) testing:  Immunoglobulin IgG (quantitative)  
    HAV total antibody  Immunoglobulin IgM (quantitative)  
    HAV IgM antibody  Phosphatidylethanol (PEth)  
Hepatis B virus (HBV) testing:  Urine Chemistry  
    Hepatitis B surface antigen (HBsAg)  Drug screen  
    Hepatitis B surface antibody (anti -HBs)  Ethyl glucuronide (EtG)  
    Hepatitis B core total antibody (anti -HBc)  Other Serology  
    Hepatitis B core IgM antibody  Anti-nuclear antibody (ANA)  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
112     Hepatitis B core IgG antibody  Anti-smooth muscle antibody (ASMA) a 
    HBV DNA b Anti-actin antibody c 
Hepatis C virus (HCV) testing:  Epstein -Barr virus (EBV) testing:  
    HCV antibody      EBV antibody  
    HCV RNA b     EBV DNA b 
Hepatitis D virus (HDV) testing:  Cytomegalovirus (CMV) testing:  
    HDV antibody      CMV antibody  
Hepatitis E virus (HEV) testing:      CMV DNA b 
    HEV IgG antibody  Herpes simplex virus (HSV) testing:  
    HEV IgM antibody      HSV (Type 1 and 2) antibody  
    HEV RNA b     HSV (Type 1 and 2) DNA b 
Microbiology d Liver kidney microsomal Type 1 (LKM -1) antibody  
Culture:   
    Blood   
    Urine   
a Not required if anti -actin antibody is tested.  
b Reflex or confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
d Assayed ONLY by [CONTACT_1697] -designated local lab oratory; no central testing available.  
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
113 10.6. Appendix 6: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow -up, and Reporting   
Refer to Appendix 3 for defin itions and procedures for recording, evaluating, follow -up, and 
reporting of all events.   
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
114 10.7. Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances   
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific tim e periods as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional circumstances are rare events  that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These di sruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_134140], regulatory bodies, and any other relevant local authorities, 
implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_517483], unless they have specific requirements in which notification is 
required, for example, upon implementation and suspension of changes. All approvals and 
notifications must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study particip ants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to continue safely in the study and maintaining the integrity of the study.  
Informed consent  
Additional consent from the participant will be obtain ed, if required, for  
 participation in remote visits, as defined in Section “Remote Visits”  
 dispensation of additional study intervention during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of t heir personal or medical information required prior to implementation of 
these activities.  
Changes in study conduct during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulation s, are not allowed.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744427] will not be considered protocol deviations:  
Remote visits  
Types of remote visits  
Telemedicine:  Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments according to the SoA, if written approval is provided by [CONTACT_103].  
Mobile healthcare: Healthcare visits may be performed by a mobile healthcare provider at 
locations other than the study site when participants cannot travel to the site due t o an 
exceptional circumstance if written approval is provided by [CONTACT_456] . 
Other alternative locations: Laboratory draws may be done at an alternate location in exceptional 
circumstances, if written approval is provided by [CONTACT_456].  
Data capture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requir ements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of central laboratory testing, except for HbA1c 
and serum glucose testing. Lilly -designated laboratory testing must be retained for HbA1c and  
serum glucose.  
The local laboratory must be qualified in accordance with applicable local regulations.  
Obtain local labs for safety hematology, chemistry, hormone panel, and urinalysis, when 
applicable, per the SoA. Safety labs should be obtained as specified in the SoA. 
All labs will be reviewed by [CONTACT_473]. Sign and date review of local labs per normal 
process and follow -up with the participant as needed. Results will not be recorded in the CRF.  
Lilly Med ical should be informed of any labs that meet criteria for temporary or permanent study 
intervention  discontinuation.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
116 Study intervention and ancillary supplies (including participant diaries)  
When a  participant is unable to go to the site to receive study supplies during normal on -site 
visits, the site should work with the sponsor to determine appropriate actions. These actions may 
include  
 asking the participant to go to the site and receive study supplies from site staff 
without completion of a full study visit 
 asking the participant’s designee to go to the site and receive study supplies on a 
participant’s behalf, and  
 arranging delivery of study supplies.  
These requirements must be met before action is taken.  
 Alternate delivery of study intervention should  be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain unchanged, including 
verification of participant’s receipt of study supplies.  
 When del ivering supplies to a location other than the study site, for example, 
participant’s home, the investigator, sponsor, or both, should ensure oversight of the 
shippi[INVESTIGATOR_51961], that is, storage 
conditions maintai ned and intact packaging upon receipt.  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
Screening period guidance  
To ensure safety of study participants, laboratory values and o ther eligibility assessments taken 
at screening or the lead -in visits are valid for a maximum of [ADDRESS_744428] ances:  
 If screening is paused for less than [ADDRESS_744429] the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and  document this confirmation in the source 
documentation.  
 If screening is paused for more than [ADDRESS_744430] be discontinued because of screening 
interruption due to an exceptional circumsta nce. This is documented as a screen 
failure in the CRF.  The participant can reconsent and be rescreened as a new 
participant. The screening procedures per the usual SoA should be followed, starting 
at the screening visit to ensure participant eligibility b y the randomization visit.  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
117 Adjustments to visit windows  
Whenever possible and safe to do so, as determined by [CONTACT_093]’s discretion, participants 
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study.  
The primary endpoint visit, Week 52  (Visit 33 ), should be completed per original schedul e 
whenever possible and safe to do so. However, the visit windows should be within ±[ADDRESS_744431] will be documented  
Sites will identify and document the details of how participants, visits types, and conducted 
activities were affected by [CONTACT_52022]. Disp ensing or shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documents at alternate locations  
Source documents generated at a location other than the study site should b e part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
118 10.8. Appendix 8: Abbreviations  and Definitions   
 
Term  Definition  
abuse  Use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
ADA  antidrug antibody  
AE adverse event  
ANCOVA  analysis of covariance  
authorized IMP  Applicable to the EU only : a medicinal product authorized in accordance with 
Regulation (EC) No 726/2004 or in any Member State concerned in accordance with 
Directive 2001/83/EC, irrespective of changes to the labeling of the medicinal product, 
which is used as an investigational medicinal product  
CI confidence interval  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery sys tem 
compliance  Adherence to all study -related, good clinical practice, and applicable regulatory 
requirements  
CRF  case report form; a printed, optical, or electronic document designed to record all of 
the protocol -required information to be reported to t he sponsor for each trial 
participant  
DID-EQ Diabetes Injection Device Experience Questionnaire  
DMC  data monitoring committee; a data-monitoring committee is a group of independent 
scientists who are appointed to monitor the safety and scientific integrity of a human 
research intervention and to make recommendations to the sponsor regarding the 
stoppi[INVESTIGATOR_31081] a study for efficacy, or for harms, or for futility. The composition of the 
committee is dependent upon the scientific skills and knowledge requ ired for 
monitoring the particular study  
DPP -[ADDRESS_744432] complaint  
DTSQ -c Diabetes Treatment Satisfaction Questionnaire - Change Version  
DTSQ -s Diabetes Treatment Satisfaction Questionnaire -Status Version  
EAS  efficacy analysis set  
ECG  electrocardiogram  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
119 ED early discontinuation  
EDC  electronic data capture  
eGFR (CKD -EPI)  estimated glomerular filtration rate (chronic kidney disease epi[INVESTIGATOR_51962])  
enroll  The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment  
enter  Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable repres entatives  
ERB  Ethical Review Board  
FBG  fasting blood glucose  
GCP  good clinical practice  
GLP -[ADDRESS_744433]  
HbA1c  hemoglobin A1c  
IB Investigator’s Brochure  
ICF informed consent form  
ICH  International Council for Harmonisation  
IEC Independent Ethics Committee  
IMP  investigational medicinal product  
A medicinal product, which is being tested or used as a reference, including as a 
placebo, in a clinical trial.  
See also “ investigational product.”  
informe d consent  A process by [CONTACT_9444] a participant voluntarily confirms their willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the participant’s decision to participate. Informed consent is documented by 
[CONTACT_3553] a written, signed, and dated informed consent form  
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment 
groups, that is conducted before the final reporting database is created or l ocked  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different fro m the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form . See also “IMP”.  
IRB Institutional Review Board  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
[ADDRESS_744434] squares  
medication error  Errors in the prescribing, dispensing, or administration of a study intervention, 
regardless of whether or not the medication is administered to the participant or the 
error leads to an AE. Medication error generally involve s a failure to uphold 1 or more 
of the 5 “rights” of medication use: the right participant, the right drug, the right dose, 
right route, and at the right time.  
In addition to the core 5 rights, the following may also represent medication errors:  
• dose om ission associated with an AE or a product complaint  
• dispensing or use of expi[INVESTIGATOR_51963]  
• use of medication past the recommended in -use date  
• dispensing or use of an improperly stored medication  
• use of an adulterated dosage form or administration technique inconsistent with the 
medication’s labeling (for example, Summary of Product Characteristics, IB, local 
label, and protocol), or  
• shared use of cartridges, prefilled pens, or both.  
misuse  use of a study intervention for self -treatment that either is inconsistent with the 
prescribed dosing regimen, indication, or both, or is obtained without a prescription  
MMRM  mixed -model repeated measures  
NIM  noninferiority margin  
participant  equivalent to CDISC term “subject”: an individual who particip ates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PK/PD  pharmacokinetics/pharmacodynamics  
PT-INR prothrombin time, INR  
SAE  serious adverse event  
SAP  statistical analysis plan  
screen  The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study  
SGLT2  sodium -glucose cotransporter 2  
SIM -Q Simplicity of Diabetes Treatment Questionnaire  
SMBG  self-monitoring of blood glucose  
T1D  Type 1 diabetes  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
121 T2D  Type 2 diabetes  
TE ADA  treatment -emergent ADA  
TEAE  treatment -emergent adverse event: an untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens 
relative to the pretreatment state, and does not necessarily have to have a causal 
relationship with this treatment  
TRIM -D Treatment -Related Impact Measure – Diabetes  
WOCBP  women of childbearing potential  
 
  
Approved on 31 May 2023 GMT
CONFIDENTIAL  I8H-MC-BDCW  (a) 
122 11. References   
Blonde L, Brunton SA, Chava P, et al. Achievement of target A1C <7.0% (<53 mmol/mol) by U.S. 
type 2 diabetes patients treated with basal insulin in both randomized controlled trials and clinical 
practice. Diabetes . 201 9;32(2) :93-103. https://doi.org/10.2337/ds17 -0082  
Bradley C, Lewis KS. Measures of psychological well -being and treatment satisfaction developed 
from the responses of people with tablet -treated diabetes. Diabet Med . 1990;7(5):445 -451. 
https://doi.org/ 10.1111/j.1464 -5491.1990.tb01421.x  
Bradley C. Diabetes Treatment Satisfaction Questionnaire: Change version for use alongside 
status version provides appropriate solution where ceiling effects occur. Diabetes Care . 
1999 ;22(3):530 -532. https://doi.org/10.2337/diacare.22.3.530  
CDC 2021. How to treat low blood sugar (hypoglycemia). Published 2021. Accessed May 02, 2023. 
https://www.cdc.gov/diabetes/basics/low -blood -sugar -treatment.html  
Heise T. The future of insulin therapy. Diabetes Res Clin Pract . 2021;175:108820. 
https://doi.org/10.1016/j.diabres.2021.108820  
Matza LS, Boye KS, Stewart KD, et al. Development of the Diabetes Injection Device 
Experience Questionnaire (DID -EQ) and Diabete s Injection Device Preference Questionnaire 
(DID -PQ). J Patient Rep Outcomes . 2018;2:43. https://doi.org/10.1186/s41687 -018-0068 -z 
[NGSP ]. Harmonizing Hemoglobin A1c Testing. IFCC Standardization of HbA1c.  Published  
2010. Accessed  May 16 , 2022. https://ngsp.org/index.asp  
Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley  & Sons Inc .;1987 . 
[LOCATION_006] National Diabetes Audit 2017. National Diabetes Audit 2016 -2017 Short Report, Care 
Processes and Treatment Targets. NHS Digital . Published November 10, 2017. Accessed 
May 02, 2023 . https://digital.nhs.uk/data -and-information/publications/statistical/national -
diabetes -audit/national -diabetes -audit -report -1-care-processes -and-treatment -targets -2016 -17 
Westfall PH , Krishen A. Optimally weighted,  fixed sequence and gatekeeper multiple testing  
procedures. J Stat Plan Inference . 2001;99(1):25 -40. https://doi.org/10.1016/S0378 -
3758(01)[ZIP_CODE] -5 
Approved on 31 May 2023 GMT
Signature [CONTACT_11032]-CLIN-109083 v1.0
Signature [CONTACT_11032]-CLIN-109083 v1.0Approval
irector
30-May-2023 18:51:05 GMT[PHONE_006]
Approval
31-May-2023 16:39:47 GMT[PHONE_006]
Approved on 31 May 2023 GMT
[COMPANY_003]
[COMPANY_003]